<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id><journal-title-group><journal-title>Translational Psychiatry</journal-title></journal-title-group><issn pub-type="epub">2158-3188</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27959333</article-id><article-id pub-id-type="pmc">5290343</article-id><article-id pub-id-type="pii">tp2016251</article-id><article-id pub-id-type="doi">10.1038/tp.2016.251</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A single high dose of dexamethasone affects the phosphorylation state of glutamate AMPA receptors in the human limbic system</article-title><alt-title alt-title-type="running">Glucocorticoids and AMPA receptors</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lopes</surname><given-names>M W</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="author-notes" rid="note1"><sup>16</sup></xref></contrib><contrib contrib-type="author"><name><surname>Leal</surname><given-names>R B</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="author-notes" rid="note1"><sup>16</sup></xref></contrib><contrib contrib-type="author"><name><surname>Guarnieri</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Schwarzbold</surname><given-names>M L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hoeller</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Diaz</surname><given-names>A P</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Boos</surname><given-names>G L</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Linhares</surname><given-names>M N</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Nunes</surname><given-names>J C</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Quevedo</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Bortolotto</surname><given-names>Z A</given-names></name><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Markowitsch</surname><given-names>H J</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Lightman</surname><given-names>S L</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="aff" rid="aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Walz</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Biochemistry, Federal University of Santa Catarina</institution>, Floran&#x000f3;polis, <country>Brazil</country></aff><aff id="aff2"><label>2</label><institution>Center for Applied Neuroscience, Hospital Universit&#x000e1;rio, Federal University of Santa Catarina</institution>, Florian&#x000f3;polis, <country>Brazil</country></aff><aff id="aff3"><label>3</label><institution>Epilepsy Center of Santa Catarina, Federal University of Santa Catarina</institution>, Florian&#x000f3;polis, <country>Brazil</country></aff><aff id="aff4"><label>4</label><institution>Neurosurgery Unit, Governador Celso Ramos Hospital</institution>, Florian&#x000f3;polis, <country>Brazil</country></aff><aff id="aff5"><label>5</label><institution>Department of Internal Medicine, Federal University of Santa Catarina</institution>, Florian&#x000f3;polis, <country>Brazil</country></aff><aff id="aff6"><label>6</label><institution>Anesthesiology Division, Hospital Governador Celso Ramos</institution>, Florian&#x000f3;polis, <country>Brazil</country></aff><aff id="aff7"><label>7</label><institution>Department of Surgery, HU, Federal University of Santa Catarina</institution>, Florian&#x000f3;polis, <country>Brazil</country></aff><aff id="aff8"><label>8</label><institution>Pathology Division, HU, Federal University of Santa Catarina</institution>, Florian&#x000f3;polis, <country>Brazil</country></aff><aff id="aff9"><label>9</label><institution>Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston</institution>, Houston, TX, <country>USA</country></aff><aff id="aff10"><label>10</label><institution>Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston,</institution> Houston, TX, <country>USA</country></aff><aff id="aff11"><label>11</label><institution>Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston</institution>, Houston, TX, <country>USA</country></aff><aff id="aff12"><label>12</label><institution>Laboratory of Neurosciences, Graduate Program in Health Sciences, University of Southern Santa Catarina</institution>, Crici&#x000fa;ma, <country>Brazil</country></aff><aff id="aff13"><label>13</label><institution>Centre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, University of Bristol</institution>, Bristol, <country>UK</country></aff><aff id="aff14"><label>14</label><institution>Physiological Psychology, University of Bielefeld</institution>, Bielefeld, <country>Germany</country></aff><aff id="aff15"><label>15</label><institution>Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, School of Clinical Sciences, Faculty of Medicine and Dentistry, University of Bristol</institution>, Bristol, <country>UK</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label><institution>Departamento de Cl&#x000ed;nica M&#x000e9;dica, 3 andar, Hospital Universit&#x000e1;rio, Universidade Federal de Santa Catarina</institution>, Florian&#x000f3;polis CEP 88.040-970, <country>Brazil</country>. E-mail: <email>rogerwalz@hotmail.com</email></corresp><fn fn-type="present-address" id="note1"><label>16</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>13</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>12</month><year>2016</year></pub-date><volume>6</volume><issue>12</issue><fpage>e986</fpage><lpage/><history><date date-type="received"><day>03</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>15</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 The Author(s)</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>The Author(s)</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><!--author-paid--><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license></permissions><abstract><p>Glucocorticoids (GC) released during stress response exert feedforward effects in the whole brain, but particularly in the limbic circuits that modulates cognition, emotion and behavior. GC are the most commonly prescribed anti-inflammatory and immunosuppressant medication worldwide and pharmacological GC treatment has been paralleled by the high incidence of acute and chronic neuropsychiatric side effects, which reinforces the brain sensitivity for GC. Synapses can be bi-directionally modifiable via potentiation (long-term potentiation, LTP) or depotentiation (long-term depression, LTD) of synaptic transmission efficacy, and the phosphorylation state of Ser831 and Ser845 sites, in the GluA1 subunit of the glutamate AMPA receptors, are a critical event for these synaptic neuroplasticity events. Through a quasi-randomized controlled study, we show that a single high dexamethasone dose significantly reduces in a dose-dependent manner the levels of GluA1-Ser831 phosphorylation in the amygdala resected during surgery for temporal lobe epilepsy. This is the first report demonstrating GC effects on key markers of synaptic neuroplasticity in the human limbic system. The results contribute to understanding how GC affects the human brain under physiologic and pharmacologic conditions.</p></abstract></article-meta></front><body><sec><title>Introduction</title><p>Stress responses initiated by environmental threats promote autonomic, endocrine, and behavioral changes that help self-preservation.<sup><xref ref-type="bibr" rid="bib1">1</xref></sup> The prefrontal cortex (PFC), amygdala (AMY) and hippocampus (HIP) are the key brain structures of the feedforward and feedback networks that mediate states of stress and fear. Glucocorticoids (GC) released during stress responses have feedforward effects in the whole brain, with a particular importance in limbic structures.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref></sup> During non-stress conditions, the PFC exerts top&#x02013;down regulation of limbic structures including the AMY, but in acute stress bottom&#x02013;up processes prevail and behavior changes from slower, highly flexible responses to faster, stereotyped reaction.<sup><xref ref-type="bibr" rid="bib3">3</xref></sup> Stress can be helpful or harmful depending on its intensity, duration and personal features.<sup><xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib4">4</xref></sup> In predisposed individuals acute and intense stress has been associated with post-traumatic stress disorder,<sup><xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib4">4</xref></sup> and chronic and repetitive stress with other psychiatric disorders, including anxiety and mood disorders.<sup><xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib5">5</xref></sup> In rodents the stress and excessive GC release reduce synaptic plasticity and dendritic spines in the PFC and HIP, impairs hippocampal neurogenesis, and increase synaptic plasticity and dendritic alterations in the AMY, which has been associated with behavioral abnormalities.<sup><xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib6">6</xref>, <xref ref-type="bibr" rid="bib7">7</xref></sup> In humans, evidence correlates the morphological, metabolic, functional, and cognitive effects of GC on limbic structures.<sup><xref ref-type="bibr" rid="bib8">8</xref>, <xref ref-type="bibr" rid="bib9">9</xref>, <xref ref-type="bibr" rid="bib10">10</xref>, <xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib12">12</xref></sup> The brain sensitivity to GC, particularly the limbic system, may contribute to the high incidence of GC-related neuropsychiatric side effects.<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> Furthermore, increased endogenous GC levels in Cushing's syndrome are commonly associated with depression, mania and anxiety.<sup><xref ref-type="bibr" rid="bib14">14</xref>, <xref ref-type="bibr" rid="bib15">15</xref></sup></p><p>Dependent on the applied stimulation frequency, active synapses are bi-directionally modifiable in mammalian brain regions such as the AMY, HIP and neocortex.<sup><xref ref-type="bibr" rid="bib16">16</xref>, <xref ref-type="bibr" rid="bib17">17</xref>, <xref ref-type="bibr" rid="bib18">18</xref></sup> The long-lasting increase of synaptic transmission, called long-term potentiation (LTP), is induced by high-frequency neuronal stimulation.<sup><xref ref-type="bibr" rid="bib16">16</xref>, <xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib20">20</xref>, <xref ref-type="bibr" rid="bib21">21</xref></sup> Decreases in synaptic efficacy are also needed to reset the synapses, and are accounted by long-term depression (LTD), after low-frequency stimulation.<sup><xref ref-type="bibr" rid="bib16">16</xref>, <xref ref-type="bibr" rid="bib17">17</xref>, <xref ref-type="bibr" rid="bib18">18</xref></sup> Pharmacological evidence &#x02018;<italic>in vivo</italic>' suggests an association between LTP and one-trial inhibitory avoidance,<sup><xref ref-type="bibr" rid="bib22">22</xref>, <xref ref-type="bibr" rid="bib23">23</xref>, <xref ref-type="bibr" rid="bib24">24</xref></sup> a fear associative memory task that induces LTP in the HIP.<sup><xref ref-type="bibr" rid="bib25">25</xref></sup> The fear conditioning, another fear associative memory task, can be inactivated and reactivated by LTD and LTP in the AMY, supporting a causal link between these synaptic processes and memory.<sup><xref ref-type="bibr" rid="bib18">18</xref></sup> Memory consolidation for both these tasks also can be modulated by GC.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib6">6</xref>, <xref ref-type="bibr" rid="bib26">26</xref>, <xref ref-type="bibr" rid="bib27">27</xref>, <xref ref-type="bibr" rid="bib28">28</xref></sup></p><p>AMPA (&#x003b1;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors (AMPARs) are heterotetrameric assemblies of GluA1&#x02013;GluA4 subunits, usually permeable to Na<sup>&#x0002b;</sup> and K<sup>&#x0002b;</sup>. Expression of Ca<sup>2&#x0002b;</sup>-permeable AMPARs, lacking GluA2 subunits (that is, GluA1 homomers) exist especially in the extrasynaptic and intracellular locations but can be recruited to synapses during neuroplasticity.<sup><xref ref-type="bibr" rid="bib29">29</xref></sup> Phosphorylation and dephosphorylation states of distinct sites of the GluA1 subunit of the AMPAR regulates the channel conductance and GluA1 synaptic membrane insertion is involved in the LTP and LTD induction.<sup><xref ref-type="bibr" rid="bib29">29</xref>, <xref ref-type="bibr" rid="bib30">30</xref>, <xref ref-type="bibr" rid="bib31">31</xref>, <xref ref-type="bibr" rid="bib32">32</xref>, <xref ref-type="bibr" rid="bib33">33</xref>, <xref ref-type="bibr" rid="bib34">34</xref></sup> Two major sites of GluA1 phosphorylation of AMPAR are studied regarding their role in neuroplasticity: (1) the Ser831, phosphorylated by Ca<sup>2&#x0002b;</sup>/calmodulin-dependent protein kinase II (CaMKII) and protein kinase C (PKC), which increases the channel conductance; (2) the Ser845, phosphorylated by cAMP-dependent protein kinase (PKA) that affects the open-channel probability of the receptor and regulates the synaptic incorporation of GluA1 subunit of AMPARs. It was reported that in naive synapses, LTD induction dephosphorylates Ser845, although in potentiated synapses the Ser831 is dephosphorylated by LTD induction. Conversely, LTP induction in naive synapses increases phosphorylation of GluA1-Ser831, whereas in depressed synapses phosphorylation of GluA1-Ser845 was enhanced.<sup><xref ref-type="bibr" rid="bib34">34</xref></sup> Serine 845 and 831 are dephosphorylated by low-frequency stimulation (LTD) in a manner dependent of protein phosphatase activity including PP1, PP2A and PP2B.<sup><xref ref-type="bibr" rid="bib32">32</xref>, <xref ref-type="bibr" rid="bib35">35</xref>, <xref ref-type="bibr" rid="bib36">36</xref></sup> Mice generated with knockin mutations in the GluA1 phosphorylation sites that shows deficits in LTD and LTP in the CA1 region of Hippocampus and have memory defects in spatial learning tasks. These results demonstrate that phosphorylation of GluA1 is critical for LTD and LTP expression and is involved in memory processing.<sup><xref ref-type="bibr" rid="bib37">37</xref></sup> Therefore, GluA1 phosphorylation of AMPARs sites at Ser831 and Ser845 sites are critical for &#x02018;<italic>in vivo</italic>' synaptic plasticity being an emerging focus as a major target for stress and GC in the limbic system.<sup><xref ref-type="bibr" rid="bib38">38</xref>, <xref ref-type="bibr" rid="bib39">39</xref>, <xref ref-type="bibr" rid="bib40">40</xref></sup></p><p>The GC effects on the phosphorylation state of GluA1-AMPA, has never been investigated in the human limbic system. Mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS) is the most common surgically remediable epileptic syndrome.<sup><xref ref-type="bibr" rid="bib41">41</xref></sup> Because surgery involves a &#x02018;standard' resection of the neocortical and mesial temporal lobe structures,<sup><xref ref-type="bibr" rid="bib41">41</xref></sup> it offers an ethical opportunity to obtain human samples of AMY and HIP under well-controlled conditions to investigate phosphorylation state of proteins. Here we present a quasi-randomized controlled study showing the effect of a single high dose of dexamethasone (DEXA), on the phosphorylation levels of GluA1-Ser845 and GluA1-Ser831 in the human AMY, head of HIP and middle temporal neocortex gyrus (CX) of surgical patients with drug resistant MTLE-HS.</p></sec><sec><title>Materials and methods</title><sec><title>Patients</title><p>We included 31 adult drug-resistant MTLE-HS patients treated surgically between May 2009 and December 2012 at the Centro de Epilepsia de Santa Catarina. They participated in a prospective study about synaptic plasticity markers in MTLE-HS. All patients had seizures that impaired awareness at least once a month (mean 7.5 per month), despite adequate treatment with at least two antiepileptic drugs (AEDs) in monotherapy. Their medical history, seizure semiology, neurological examination, psychiatric and neuropsychological evaluation, interictal and ictal surface video-EEG, and magnetic resonance imaging findings were consistent with unilateral MTLE-HS.<sup><xref ref-type="bibr" rid="bib41">41</xref>, <xref ref-type="bibr" rid="bib42">42</xref>, <xref ref-type="bibr" rid="bib43">43</xref>, <xref ref-type="bibr" rid="bib44">44</xref>, <xref ref-type="bibr" rid="bib45">45</xref>, <xref ref-type="bibr" rid="bib46">46</xref>, <xref ref-type="bibr" rid="bib47">47</xref></sup></p><p>Controlled clinical variables included gender, race, side of HS, age, disease duration, age of recurrent seizures onset, psychiatric comorbidities and quality of life.<sup><xref ref-type="bibr" rid="bib41">41</xref>, <xref ref-type="bibr" rid="bib42">42</xref>, <xref ref-type="bibr" rid="bib43">43</xref>, <xref ref-type="bibr" rid="bib44">44</xref>, <xref ref-type="bibr" rid="bib45">45</xref>, <xref ref-type="bibr" rid="bib46">46</xref>, <xref ref-type="bibr" rid="bib47">47</xref></sup> The AEDs used were carbamazepine, phenobarbital, diphenilhydantoin, valproic acid, lamotrigine or topiramate, associated or not with benzodiazepines (clobazam or clonazepam). The protocol was approved by the Ethics Committee for Human Research of Universidade Federal de Santa Catarina (365-FR304969). Written informed consent was obtained from all patients.</p></sec><sec><title>Anesthesia protocol</title><p>The anesthetic protocol, except the DEXA treatment, were the same for all patients. Anesthesia started between 0730 hours to 0830 hours with intravenous (i.v.) bolus of propofol (2&#x02009;mg&#x02009;kg<sup>&#x02212;1</sup>), fentanyl (2&#x02009;&#x003bc;g&#x02009;kg<sup>&#x02212;1</sup>) and rocuronium (0.9&#x02009;mg&#x02009;kg<sup>&#x02212;1</sup>), followed by i.v. remiphentanil infusion (0.1 to 0.2&#x02009;&#x003bc;g&#x02009;kg<sup>&#x02212;1</sup>&#x02009;min) and isofluorane inhalation (0.5 to 0.6 M.A.C.). Hydration was done with isotonic saline (1.2&#x02009;ml&#x02009;kg<sup>&#x02212;1</sup>&#x02009;h) plus the half volume of diuresis. Cephalotine (30&#x02009;mg&#x02009;kg<sup>&#x02212;1</sup>) was given 30&#x02009;min before the anesthesia. Oral AEDs were maintained until the day of surgery (0600 hours). Patients received 20&#x02009;mg&#x02009;kg<sup>&#x02212;1</sup> of phenytoin i.v. 12&#x02009;h before the surgery and 5&#x02009;mg&#x02009;kg<sup>&#x02212;1</sup> i.v. after the brain samples were collected. Patients under phenytoin at home received only their morning oral dose and the intraoperative dose after the brain samples were collected.</p></sec><sec><title>Dexamethasone treatment and study design</title><p>After the first 11 patients were included in the study, the anesthesiology team decided to use DEXA (10&#x02009;mg i.v. bolus) immediately after intubation as an adjunctive anti-inflammatory and anti-emetic therapy.<sup><xref ref-type="bibr" rid="bib48">48</xref></sup> The DEXA infusion was not based on any clinical data. This change in the anesthesia protocol gave us the opportunity to design this quasi-randomized controlled study. The DEXA dose was calculated dividing 10&#x02009;mg by the patient weight. The mean (s.e.) DEXA dose was 0.1575 (0.006) &#x02009;mg&#x02009;kg<sup>&#x02212;1</sup> (range 0.11 to 0.2). Although this selective GR agonist differs from endogenous cortisol in many aspects of its transcriptional activity, this dose results in at least 27 times the effect of a daily adult human secretion of cortisol.<sup><xref ref-type="bibr" rid="bib49">49</xref></sup></p></sec><sec><title>Surgery, intraoperative variables and brain tissue sampling</title><p>The surgeries and tissue sampling were done by the same neurosurgeon (MNL) and the principal investigator (RW) as previously described.<sup><xref ref-type="bibr" rid="bib50">50</xref></sup> The samples came from the brain tissue removed during a standard anterior and temporal lobectomy (ATL) procedure and were immediately frozen in liquid nitrogen and stored in &#x02212;80&#x02009;<sup>o</sup>C freezer until the analyses. The sampling course is presented in <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure 1</xref>. The temporal lobe resection included the middle and inferior temporal gyri extended up to 4&#x02009;cm posterior from the temporal pole. Prior to the cortical resection, a 1&#x02009;cm<sup>2</sup> sample of the CX localized 3&#x02009;cm posterior to the temporal pole was gently dissected from the white matter. After assessing the mesial temporal region, 2/3 of the AMY were collected including its basal and the lateral nucleus. Both AMY and CX were collected without previous thermocoagulation. After AMY resection, the HIP was removed &#x02018;<italic>en bloc</italic>' and its head and part of the body were quickly dissected on ice-refrigerated glass. The time of HIP manipulation since the electrocoagulation of its vascular supply start until its resection was controlled. Arterial blood gases, electrolytes, hematocrit, hemoglobin, acid-basic, mean arterial pressure heart and respiratory rate parameters during the AMY/HIP sampling were controlled. The anesthesia duration until each brain sample was controlled as well. The hemodynamic and respiratory parameters remained stable and no surgical complication was reported.</p></sec><sec><title>Biochemical analysis</title><p>Biochemical analysis was blinded for all clinical data. All samples were homogenized by the same researchers (MWL) in the same day, placed in liquid nitrogen, and storage at &#x02212;80&#x02009;<sup>o</sup>C until the analysis. The quantification of phosphorylation levels and total amount of the target proteins were performed by western blot as we described previously.<sup><xref ref-type="bibr" rid="bib51">51</xref>, <xref ref-type="bibr" rid="bib52">52</xref>, <xref ref-type="bibr" rid="bib53">53</xref>, <xref ref-type="bibr" rid="bib54">54</xref>, <xref ref-type="bibr" rid="bib55">55</xref>, <xref ref-type="bibr" rid="bib56">56</xref></sup> Protein content was determined by Peterson's method.<sup><xref ref-type="bibr" rid="bib57">57</xref></sup> Proteins were detected after overnight incubation with specific antibodies diluted in TBS with tween with 2&#x00025; bovine serum albumin in a 1:1000 dilution (anti-phospho-GluA1-Ser831 (Sigma-Aldrich, St Louis, MO, USA, A4352); anti-phospho-GluA1-Ser845 (Sigma-Aldrich, A4477); anti-total-GluA1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-13152); anti-EAAT1 (Cell Signaling, Beverly, MA, USA, &#x00023;5684); anti-EAAT2 (Cell Signaling,&#x00023;3838); anti-PP1ca (Santa Cruz Biotechnology,sc-7482); anti-phospho-CaMKII (Cell Signaling, &#x00023;3361); anti-total-CaMKII (Cell Signaling, &#x00023;3362); anti-GFAP (Cell Signaling, &#x00023;3670) and anti-total-AKT (Cell Signaling, &#x00023;9272)); 1:2000 (anti-phospho-ERK1/2 (Sigma-Aldrich, M8159); anti-phospho-AKT (Sigma-Aldrich, P4112); anti-phospho-PKA substrates (Cell Signaling, &#x00023;9624) and anti-phospho-PKC substrates (Cell Signaling, &#x00023;2261)), 1:5000 (anti-phospho-JNK p54/46 (Sigma-Aldrich, J4750) and anti-total-JNK p54/46 (Sigma-Aldrich, J4500)); 1:10&#x02009;000 (anti-phospho-p38MAPK (Merck-Millipore, Temecula, CA, USA, 05-1059) and anti-total-p38MAPK (Sigma-Aldrich, M0800)) and 1:40&#x02009;000 (anti-total-ERK1/2 (Sigma-Aldrich, M5670)). All membranes were incubated with anti-&#x003b2;-actin (Santa Cruz Biotechnology, sc-47778, 1:2000) antibody to control the protein load for each sample on the gel. The phosphorylation level was determined as a ratio of the optic density (OD) of the phosphorylated band/the OD of the total band. The immunocontent was determined as a ratio of the OD of the protein band by the OD of the &#x003b2;-actin band. The bands were quantified using the Scion Image software (Frederick, MD, USA).</p><p>Owing to the lack of adequate brain tissue samples from healthy controls and to avoid intra-day biases of western blot quantification, an internal control (IC) coming from three pooled HIP homogenized in the same way and time as all the studied samples was applied in all electrophoresis. The strategy also allows comparisons of variations in the phosphoprotein percentage according to brain structures and clinical parameters among the patients. The OD ratio (phospho/total or total/&#x003b2;-actin) for each target protein in the IC was considered 100&#x00025;. The OD ratio of each protein analyzed in the samples was correlated as a percentage of the IC. When ERK1 phosphorylation was analyzed, for example, and the OD ratio (OD phospho-ERK1/OD total-ERK1) of the IC was 0.75 and the OD ratio for the investigated sample was 0.9; this means that the OD ratio of the investigated sample was 120&#x00025; of the IC.</p></sec><sec><title>Statistical analysis</title><p>All the neurochemical and clinical variables showed a parametric distribution (Kolmogorov&#x02013;Smirnov). The distribution of neurochemical, clinical and laboratory variables according to DEXA treatment were analyzed by the Student's <italic>t</italic>-test, analysis of variance or Fisher's exact test. Comparisons of GluA1-Ser831 and GluA1-Ser845 phosphorylation levels in the CX, AMY and HIP between patients who received or not DEXA treatment were analyzed by Student's <italic>t</italic>-test. To reduce the possibility of a type I error due to multiple comparisons (two GluA1 phosphorylation sites in three structures) the level of significance should be <italic>P</italic>&#x0003c;0.0085. Multiple linear regressions analyses were done to determine the independent effect of DEXA on the variation of the phosphorylation levels of the serine 831 and 845 of the GluA1 subunit of glutamate AMPARs. Variables showing associations with <italic>P</italic>&#x0003c;0.15 in the univariate analysis were included in the multiple linear regressions analysis. For the final regression model the <italic>P</italic>&#x0003c;0.01 were considered statistically significant.</p></sec></sec><sec><title>Results</title><p><xref rid="tbl1" ref-type="table">Table 1</xref> shows the clinical, demographic, and laboratory variables of patients according to DEXA treatment. There were trends for imbalances between DEXA and non-DEXA groups according to gender (<italic>P</italic>=0.13), AEDs regimen (<italic>P</italic>=0.04), phenobarbital use (<italic>P</italic>=0.13), monthly frequency of seizures (<italic>P</italic>=0.04), intraoperative serum glucose (<italic>P</italic>=0.10) and storage time of samples (<italic>P</italic>=0.05).</p><p>The phosphorylation profile according to DEXA groups is shown in <xref rid="tbl2" ref-type="table">Table 2</xref>. The AMY levels of P-GluA1-Ser831 were 20.9&#x00025; lower in the DEXA-treated patients in comparison with non-DEXA group (<italic>P</italic>=0.0003). There were trends for lower levels of P-GluA1-Ser831 in the CX (<italic>P</italic>=0.06) and HIP (<italic>P</italic>=0.10) among patients treated with DEXA. There was a trend higher P-GluA1-Ser845 levels in the CX (<italic>P</italic>=0.02), but not in the HIP and AMY of DEXA-treated patients (<xref rid="tbl3" ref-type="table">Table 3</xref>).</p><p>The <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure 2a</xref> shows a dose-dependent effect of DEXA on P-GluA1-Ser831 levels in the AMY (<italic>r</italic>=0.69; <italic>r</italic><sup>2</sup>=0.48; <italic>P</italic>=0.0002). Because the non-normal distribution of DEXA dose related to patients who did not receive DEXA, a linear regression also was performed only with patients who received DEXA (<italic>n</italic>=21; <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure 2b</xref>). This analysis confirmed the dose-dependent decrease of P-GluA1-Ser831 levels in the AMY by DEXA treatment (<italic>r</italic>=0.66; <italic>r</italic><sup>2</sup>=0.43; <italic>P</italic>=0.002). The observed association was not affected by the order of surgery (<italic>P</italic>=0.79), reducing the possibility of non-identified confounders related to tissue sampling of non-DEXA group (data not shown).</p><p>To exclude confounding biases resulting from imbalances in the distribution of gender, AEDs regimen, phenobarbital use, frequency of seizures, intraoperative serum glucose and storage time of samples, the association between the AMY levels of P-GluA1-Ser831 and these variables were analyzed together with DEXA treatment. There were trends for association between AMY levels of P-GluA1-Ser831 and gender (<italic>P</italic>=0.02) and serum glucose (<italic>P</italic>=0.12) (top of Table 3). After a multiple linear regression (bottom of Table 3), only DEXA treatment remained independently associated with P-GluA1-Ser831 levels in AMY. The trend for association between DEXA treatment and P-GluA1-Ser831 and P-GluA1-Ser845 levels in the CX and P-GluA1-Ser845 levels in the HIP became non-significant (<italic>P</italic>&#x0003e;0.15) after controlling for imbalances in the clinical variables distribution by multiple linear regressions (data not shown).</p><p>The rapid effect of DEXA on the AMY levels of P-GluA1-Ser831 could be non-genomic changes on the PKC activity and P-CaMKII levels, or imbalance of PP1 levels between DEXA and non-DEXA groups. <xref rid="tbl4" ref-type="table">Table 4</xref> shows that DEXA treatment decreases the mean levels of P-CaMKII in the AMY (<italic>P</italic>=0.02) by 22.4&#x00025;, despite a trend (<italic>P</italic>=0.08) for higher levels of the total CaMKII in the DEXA treated patients. There were no differences in the PP1ca levels or PKC activity in the AMY between DEXA and non-DEXA groups. DEXA also had no effect on the AMY levels of PKA activity, P-ERK1, P-ERK2, P-JNK1, P-JNK2, P-AKT and P-p38 (<italic>P</italic>&#x0003e;0.29), excluding a non-specific effect of DEXA on kinases in general.</p><p>MTLE-HS patients show a variable degree of AMY neuronal loss and gliosis.<sup><xref ref-type="bibr" rid="bib54">54</xref></sup> We controlled the AMY levels of total GluA1 subunits. Variations in the astrogliosis were controlled determining the levels of GFAP and astrocytes glutamate transporters (EAAT1/2). There were no differences in the AMY levels of GluA1 subunits, GFAP, EAAT1 and 2 between DEXA and non-DEXA groups (<xref rid="tbl4" ref-type="table">Table 4</xref>). Representative western blot results are shown in the <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure 3</xref>.</p></sec><sec><title>Discussion</title><p>To the best of our knowledge, this is the first report showing the GC effects on synaptic neuroplasticity biomarkers in the human limbic system. We show that 4&#x02009;h after a high dose of DEXA the AMY levels of P-GluA1-Ser831, but not P-GluA1-Ser845, decrease significantly in MTLE-HS patients. These findings indicate that DEXA treatment shifts the serine 831 residue of the GluA1-AMPAR to a dephosphorylated state in the AMY. Notably, in the same structure we also observed a reduction in the levels of P-CaMKII(Thr286), indicating a reduction in the autonomous activity of CaMKII activity.<sup><xref ref-type="bibr" rid="bib32">32</xref>, <xref ref-type="bibr" rid="bib58">58</xref>, <xref ref-type="bibr" rid="bib59">59</xref></sup> DEXA did not affect the PKC activity or PP1ca levels in AMY.</p><p>The effects could not be attributed to imbalances in the distribution of demographic, clinical, radiological, intraoperative and neurochemical variables of our patients. A trend for lower levels of P-GluA1-Ser831 was also observed in the HIP and CX, but the possibility of a false negative result related to the small sample size cannot be completely ruled out.</p><p>The AMY is particularly sensitive to rapid responses to GC both in animals<sup><xref ref-type="bibr" rid="bib60">60</xref>, <xref ref-type="bibr" rid="bib61">61</xref></sup> and in man.<sup><xref ref-type="bibr" rid="bib62">62</xref></sup> Furthermore, in an <italic>ex vivo</italic> rodent study, using lower concentrations of exogenous GC than in the current study, we have shown that both a stressor or the administration of exogenous GC affects both the physiology of AMPARs and neuroplasticity.<sup><xref ref-type="bibr" rid="bib40">40</xref></sup> Brief restraint or DEXA administration to rats increases the surface expression of GluA1 (but not the GluA2 subunit) and the magnitude of electrically induced LTP in the HIP. Furthermore, 60&#x02009;min after the restraint stress or slice incubation with corticosterone or DEXA for 30&#x02009;min the serine 845 residue phosphorylation levels of the of GluA1 subunit increases in the HIP. The effect is dependent on GC receptors and PKA, but independent of NMDARs.<sup><xref ref-type="bibr" rid="bib40">40</xref></sup> Corticosterone increases GluA2-AMPAR surface mobility in a time-dependent manner (peak in 15&#x02009;min), thereby conditioning the extent to which chemical LTP stimuli effectively increase GluA2 synaptic content during synaptic potentiation in the HIP.<sup><xref ref-type="bibr" rid="bib39">39</xref></sup> In addition, corticosterone also increases GluA1-AMPAR surface trafficking.<sup><xref ref-type="bibr" rid="bib39">39</xref></sup> The phosphorylation state of Ser831 and Ser845 of GluA1-AMPAR was variable according to different studies, depending on the brain region, stress type applied or duration and sampling time after stress.<sup><xref ref-type="bibr" rid="bib63">63</xref></sup></p><p>Karst <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib64">64</xref></sup> described that the exposure to two pulses of corticosterone (10 to 20&#x02009;min pulse duration with 1 to 3&#x02009;h pulse interval) enhances the miniature excitatory postsynaptic currents (mEPSC) frequency in CA1 pyramidal cells of mice. By contrast, basolateral amygdala (BLA) neurons responded to the first pulse with increased mEPSC frequency, but with a decreased mEPSC frequency to a second pulse. Furthermore, in BLA cells from mice exposed to restraint stress before slice preparation, corticosterone rapidly decreased mEPSC frequency, an effect that is dependent on the non-genomic activation of mineralocorticoid receptors. Although cross-species implications can be problematical, it is certainly worth pointing out that our subjects would undoubtedly have had some degree of pre-surgical hospitalization stress prior to receiving DEXA with subsequent reduction of the AMY levels of P-GluA1-Ser831. This is a neurochemical marker which has been associated with the synaptic depotentiation to the naive state from a potentiated state. Interestingly, compatible with a rapid non-transcriptional effect, Lovallo <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib65">65</xref></sup> showed a reduction of the BOLD signals in both the AMY and HIP 15&#x02013;18&#x02009;min after the injection of a small hydrocortisone dose. The relationship between this GC-related effect on BOLD signal and the synaptic potentiation or AMPA phosphorylation state in the limbic system is unknown. The AMY is a central structure in the processing of emotional components of memory, coding social and biological meanings of events.<sup><xref ref-type="bibr" rid="bib66">66</xref>, <xref ref-type="bibr" rid="bib67">67</xref>, <xref ref-type="bibr" rid="bib68">68</xref>, <xref ref-type="bibr" rid="bib69">69</xref>, <xref ref-type="bibr" rid="bib70">70</xref></sup> Clinical findings suggest that the AMY is necessary for modulating negative and positive arousing stimuli during encoding, indicating its involvement in processing biologically relevant stimuli independently of their valence.<sup><xref ref-type="bibr" rid="bib67">67</xref>, <xref ref-type="bibr" rid="bib68">68</xref></sup> These hypotheses received support by recent findings showing the BLA is a site of divergence for circuits mediating positive and negative emotional or motivational valence.<sup><xref ref-type="bibr" rid="bib69">69</xref></sup> The role of GC on the synaptic plasticity of neurons participating in the positive and negative valence-circuits deserve further investigation.</p><p>The results help not only to understand the mechanisms involved in the human brain modulation by the stress hormones, but also the common side effects related to a worldwide frequently prescribed class of pharmaceuticals. The DEXA dose used in our patients (or an equipotent dose of other GC) is commonly used in clinical practice. A large study examining the effects of oral GC treatment (<italic>n</italic>=786&#x02009;868 courses) showed an overall incidence of 15.7 per 100 person-years at risk of adverse neuropsychiatric outcomes, and 22.2 per 100 person-years at risk for patients on their first course of GC<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> The outcomes included depression, delirium, mania, panic disorder and suicidal behavior. Considering the critical role of the GluA1 phosphorylation at Ser831 and Ser845 sites for <italic>in vivo</italic> synaptic plasticity,<sup><xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib25">25</xref>, <xref ref-type="bibr" rid="bib37">37</xref></sup> we believe the observed effect of DEXA in the limbic system of our patients may be, at least in part, related to the high incidence of adverse neuropsychiatric side-effects during GC treatments. This hypothesis is in agreement with a previous study showing the association between the GRIA1 gene, that encode the GluR1 AMPAR, and psychiatric disorders. A combined linkage analysis of 60 families from National Institute of Mental Health Bipolar Genetics Initiative (NIMH-BPGI) suggested an association between a SNP in the second intron on the <italic>GRIA1</italic> gene and psychotic bipolar disorder.<sup><xref ref-type="bibr" rid="bib71">71</xref></sup> A case&#x02013;control study showed that two specific polymorphisms for the GRA1 were associated with schizophrenia in Italians.<sup><xref ref-type="bibr" rid="bib72">72</xref></sup></p><p>Recently the role of the dually phosphorylated GluR1 AMPAR at S831 and S845 on synaptic plasticity was questioned by Hosokawa <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib73">73</xref></sup> Using Phos-tag SDS-PAGE they found the majority of synapses did not contain any phosphorylated AMPAR and the amount of phosphorylated GluA1 was very low. Although the neuronal stimulation (chemical LTP) and learning (inhibitory avoidance) increased phosphorylation, the proportion also was still low. In contrast, Diering <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib74">74</xref></sup> using a variety of measurement methods, showed a large fraction of synapses positive for phospho-GluA1&#x02013;containing AMPARs, were highly responsive to numerous physiologically relevant &#x02018;<italic>in vivo</italic>' and &#x02018;<italic>in vitro</italic>' stimuli. Their results support the large body of research indicating a prominent role of GluA1 phosphorylation in synaptic plasticity. This controversy has no implications for the analysis of our results because we demonstrated significant changes in the percentage of the GluA1 subunit phosphorylation that was controlled for the total amount of phosphorylated AMPAR in both investigated groups.</p><p>There are, of course, limitations to our study. We cannot exclude the observed effects of DEXA could be, at least to some degree, related to the epilepsy background and the related pathologic, clinical and pharmacological variables not occurring in people without epilepsy. The possibility of false negatives resulting from the relatively small sample size and the limitation to one single time point for tissue sampling need to be considered. This limitation is inherent to western blot studies applied to proteins phosphorylation analysis in which all samples must be homogenized in the same day and conditions to avoid significant inter-day variability. The inclusion of different time points of DEXA treatment is not clinically feasible considering the patients receive the DEXA treatment at the anesthesia induction and the tissue sampling was dependent of the time of surgery itself. The results come from patients with an epileptic syndrome showing structural and functional neuroplasticity changes including a variable loss of neurons and gliosis in the analyzed structures.<sup><xref ref-type="bibr" rid="bib42">42</xref>, <xref ref-type="bibr" rid="bib75">75</xref></sup> The possible imbalances of structural changes between the investigated groups were controlled by corrections for the protein amount, distribution of gliosis markers, glutamate transporters and glutamate subunit receptors. The criticism about the non-use of a classic randomization is minimized because: (i) patients were included consecutively and the treatment allocation was not based on any predetermined variable or specific clinical indication and; (ii) data collection was done in a prospective way, under exhaustive cautions about the confounding variables following a predetermined approved research protocol.</p><p>To summarize, a single high dose of i.v. DEXA reduces significantly the levels of P-CaMKII and P-GluA1-Ser831 in the AMY of MTLE-HS patients in a dose-dependent manner. These effects on the signal transduction molecules and synaptic neuroplasticity in the limbic system contribute to a better understanding the GC effects in the human brain under physiologic and pharmacologic conditions.</p></sec></body><back><ack><p>This work was supported by PRONEX Program (Programa de N&#x000fa;cleos de Excel&#x000ea;ncia - NENASC Project) of FAPESC-CNPq-MS, Santa Catarina Brazil (process 56802/2010). Professor Hans J. Markowitsch is a special visitor professor of UFSC (PVE Fellowship&#x02014;CNPq 406929/2013-0). The Translational Psychiatry Program (USA) is funded by the Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth). Laboratory of Neurosciences (Brazil) is one of the centers of the National Institute for Molecular Medicine (INCT-MM) and one of the members of the Center of Excellence in Applied Neurosciences of Santa Catarina State (NENASC). Its research is supported by grants from CNPq (JQ), FAPESC (JQ); Instituto C&#x000e9;rebro e Mente (JQ) and UNESC (JQ). RBL, KL, JQ and RW are Researchers Fellows from CNPq (Brazilian Council for Scientific and Technologic Development, Brazil). SLL is supported by MRC, BBSRC and Wellcome Trust (UK) and ZAB is supported by MRC and BBSRC (UK).</p></ack><fn-group><fn><p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)</p></fn></fn-group><notes><p>The authors declare no conflict of interest.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal">Rodrigues SM, LeDoux JE, Sapolsky RM. <article-title>The influence of stress hormones on fear circuitry</article-title>. <source>Annu Rev Neurosci</source>
<year>2009</year>; <volume>32</volume>: <fpage>289</fpage>&#x02013;313.<pub-id pub-id-type="pmid">19400714</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal">de Celis MFR, Bornstein SR, Androutsellis-Theotokis A, Andoniadou CL, Licinio J, Wong M-L et al. <article-title>The effects of stress on brain and adrenal stem cells</article-title>. <source>Mol Psychiatry</source>
<year>2016</year>; <volume>21</volume>: <fpage>590</fpage>&#x02013;593.<pub-id pub-id-type="pmid">26809844</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal">Arnsten AFT. <article-title>Stress signalling pathways that impair prefrontal cortex structure and function</article-title>. <source>Nat Rev Neurosci</source>
<year>2009</year>; <volume>10</volume>: <fpage>410</fpage>&#x02013;422.<pub-id pub-id-type="pmid">19455173</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal">Kessler RC, Rose S, Koenen KC, Karam EG, Stang PE, Stein DJ et al. <article-title>How well can post-traumatic stress disorder be predicted from pre-trauma risk factors? An exploratory study in the WHO World Mental Health Surveys</article-title>. <source>World Psychiatry</source>
<year>2014</year>; <volume>13</volume>: <fpage>265</fpage>&#x02013;274.<pub-id pub-id-type="pmid">25273300</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal">Sapolsky RM. <article-title>Stress and the brain: individual variability and the inverted-U</article-title>. <source>Nat Neurosci</source>
<year>2015</year>; <volume>18</volume>: <fpage>1344</fpage>&#x02013;1346.<pub-id pub-id-type="pmid">26404708</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal">Kim JJ, Diamond DM, Haven N, Blvd BBD. <article-title>The stressed hippocampus, synaptic plasticity and lost memories</article-title>. <source>Nat Rev Neurosci</source>
<year>2002</year>; <volume>3</volume>: <fpage>453</fpage>&#x02013;462.<pub-id pub-id-type="pmid">12042880</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal">Mitra R, Sapolsky RM. <article-title>Acute corticosterone treatment is sufficient to induce anxiety and amygdaloid dendritic hypertrophy</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2008</year>; <volume>105</volume>: <fpage>5573</fpage>&#x02013;5578.<pub-id pub-id-type="pmid">18391224</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal">Henckens MJaG, van Wingen Ga, Jo&#x000eb;ls M, Fern&#x000e1;ndez G. <article-title>Time-dependent effects of cortisol on selective attention and emotional interference: a functional MRI study</article-title>. <source>Front Integr Neurosci</source>
<year>2012</year>; <volume>6</volume>: <fpage>66</fpage>.<pub-id pub-id-type="pmid">22973203</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal">Henckens MJAG, Wingen GA, van, Jo&#x000eb;ls M, Fern&#x000e1;ndez G. <article-title>Time-dependent effects of corticosteroids on human amygdala processing</article-title>. <source>J Neurosci</source>
<year>2010</year>; <volume>30</volume>: <fpage>12725</fpage>&#x02013;12732.<pub-id pub-id-type="pmid">20861377</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal">Sapolsky RM. <article-title>Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders</article-title>. <source>Arch Gen Psychiatry</source>
<year>2000</year>; <volume>57</volume>: <fpage>925</fpage>&#x02013;935.<pub-id pub-id-type="pmid">11015810</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal">Starkman MN, Gebarski SS, Berent S, Schteingart DE. <article-title>Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome</article-title>. <source>Biol Psychiatry</source>
<year>1992</year>; <volume>32</volume>: <fpage>756</fpage>&#x02013;765.<pub-id pub-id-type="pmid">1450290</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal">Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. <article-title>Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease</article-title>. <source>Biol Psychiatry</source>
<year>1999</year>; <volume>46</volume>: <fpage>1595</fpage>&#x02013;1602.<pub-id pub-id-type="pmid">10624540</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal">Fardet L, Petersen I, Nazareth I. <article-title>Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care</article-title>. <source>Am J Psychiatry</source>
<year>2012</year>; <volume>169</volume>: <fpage>491</fpage>&#x02013;497.<pub-id pub-id-type="pmid">22764363</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal">Cohen SI. <article-title>Cushing's syndrome: a psychiatric study of 29 patients</article-title>. <source>Br J Psychiatry</source>
<year>1980</year>; <volume>136</volume>: <fpage>120</fpage>&#x02013;124.<pub-id pub-id-type="pmid">7370477</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal">Sonino N, Fava GA. <article-title>Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment</article-title>. <source>CNS Drugs</source>
<year>2001</year>; <volume>15</volume>: <fpage>361</fpage>&#x02013;373.<pub-id pub-id-type="pmid">11475942</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal">Bear MF. <article-title>A synaptic basis for memory storage in the Cereb Cortex</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>1996</year>; <volume>93</volume>: <fpage>13453</fpage>&#x02013;13459.<pub-id pub-id-type="pmid">8942956</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal">Bear MF, Abraham WC. <article-title>Long-term depression in hippocampus</article-title>. <source>Annu Rev Neurosci</source>
<year>1996</year>; <volume>19</volume>: <fpage>437</fpage>&#x02013;462.<pub-id pub-id-type="pmid">8833450</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal">Nabavi S, Fox R, Proulx CD, Lin JY, Tsien RY, Malinow R. <article-title>Engineering a memory with LTD and LTP</article-title>. <source>Nature</source>
<year>2014</year>; <volume>511</volume>: <fpage>348</fpage>&#x02013;352.<pub-id pub-id-type="pmid">24896183</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal">Huang YY, Kandel ER. <article-title>Postsynaptic induction and PKA-dependent expression of LTP in the lateral amygdala</article-title>. <source>Neuron</source>
<year>1998</year>; <volume>21</volume>: <fpage>169</fpage>&#x02013;178.<pub-id pub-id-type="pmid">9697861</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal">Martin SJ, Grimwood PD, Morris RG. <article-title>Synaptic plasticity and memory: an evaluation of the hypothesis</article-title>. <source>Annu Rev Neurosci</source>
<year>2000</year>; <volume>23</volume>: <fpage>649</fpage>&#x02013;711.<pub-id pub-id-type="pmid">10845078</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal">Bliss TV, Collingridge GL. <article-title>A synaptic model of memory: long-term potentiation in the hippocampus</article-title>. <source>Nature</source>
<year>1993</year>; <volume>361</volume>: <fpage>31</fpage>&#x02013;39.<pub-id pub-id-type="pmid">8421494</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal">Jerusalinsky D, Ferreira MBC, Walz R, Da Silva RC, Bianchin M, Ruschel AC et al. <article-title>Amnesia by post-training infusion of glutamate receptor antagonists into the amygdala, hippocampus, and entorhinal cortex</article-title>. <source>Behav Neural Biol</source>
<year>1992</year>; <volume>58</volume>: <fpage>76</fpage>&#x02013;80.<pub-id pub-id-type="pmid">1417675</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal">Izquierdo I, Medina JH, Bianchin M, Walz R, Zanatta MS, Da Silva RC et al. <article-title>Memory processing by the limbic system: role of specific neurotransmitter systems</article-title>. <source>Behav Brain Res</source>
<year>1993</year>; <volume>58</volume>: <fpage>91</fpage>&#x02013;98.<pub-id pub-id-type="pmid">7907882</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal">Walz R, Roesler R, Quevedo J, Sant'Anna MK, Madruga M, Rodrigues C et al. <article-title>Time-dependent impairment of inhibitory avoidance retention in rats by posttraining infusion of a mitogen-activated protein kinase kinase inhibitor into cortical and limbic structures</article-title>. <source>Neurobiol Learn Mem</source>
<year>2000</year>; <volume>73</volume>: <fpage>11</fpage>&#x02013;20.<pub-id pub-id-type="pmid">10686120</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal">Whitlock JR, Heynen AJ, Shuler MG, Bear MF. <article-title>Learning induces long term potentiation in the hippocampus</article-title>. <source>Science</source>
<year>2006</year>; <volume>313</volume>: <fpage>1093</fpage>&#x02013;1097.<pub-id pub-id-type="pmid">16931756</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal">McGaugh JL, Roozendaal B. <article-title>Role of adrenal stress hormones in forming lasting memories in the brain</article-title>. <source>Curr Opin Neurobiol</source>
<year>2002</year>; <volume>12</volume>: <fpage>205</fpage>&#x02013;210.<pub-id pub-id-type="pmid">12015238</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal">Roesler R, Vianna MR, de-Paris F, Quevedo J. <article-title>Memory-enhancing treatments do not reverse the impairment of inhibitory avoidance retention induced by NMDA receptor blockade</article-title>. <source>Neurobiol Learn Mem</source>
<year>1999</year>; <volume>72</volume>: <fpage>252</fpage>&#x02013;258.<pub-id pub-id-type="pmid">10536102</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal">Roozendaal B, Brunson KL, Holloway BL, McGaugh JL, Baram TZ. <article-title>Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2002</year>; <volume>99</volume>: <fpage>13908</fpage>&#x02013;13913.<pub-id pub-id-type="pmid">12361983</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal">Henley JM, Wilkinson Ka. <article-title>Synaptic AMPA receptor composition in development, plasticity and disease</article-title>. <source>Nat Rev Neurosci</source>
<year>2016</year>; <volume>17</volume>: <fpage>337</fpage>&#x02013;350.<pub-id pub-id-type="pmid">27080385</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal">Huganir RL, Nicoll RA. <article-title>AMPARs and synaptic plasticity: the last 25 years</article-title>. <source>Neuron</source>
<year>2013</year>; <volume>80</volume>: <fpage>704</fpage>&#x02013;717.<pub-id pub-id-type="pmid">24183021</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal">Wang JQ, Guo M-L, Jin D-Z, Xue B, Fibuch EE, Mao L-M. <article-title>Roles of subunit phosphorylation in regulating glutamate receptor function</article-title>. <source>Eur J Pharmacol</source>
<year>2014</year>; <volume>728</volume>: <fpage>183</fpage>&#x02013;187.<pub-id pub-id-type="pmid">24291102</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal">Woolfrey KM, Dell'Acqua ML. <article-title>Coordination of protein phosphorylation and dephosphorylation in synaptic plasticity</article-title>. <source>J Biol Chem</source>
<year>2015</year>; <volume>290</volume>: <fpage>28604</fpage>&#x02013;28612.<pub-id pub-id-type="pmid">26453308</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal">Esteban JA, Shi S-H, Wilson C, Nuriya M, Huganir RL, Malinow R. <article-title>PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity</article-title>. <source>Nat Neurosci</source>
<year>2003</year>; <volume>6</volume>: <fpage>136</fpage>&#x02013;143.<pub-id pub-id-type="pmid">12536214</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal">Lee HK, Barbarosie M, Kameyama K, Bear MF, Huganir RL. <article-title>Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity</article-title>. <source>Nature</source>
<year>2000</year>; <volume>405</volume>: <fpage>955</fpage>&#x02013;959.<pub-id pub-id-type="pmid">10879537</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal">Huang CC, Liang YC, Hsu KS. <article-title>Characterization of the mechanism underlying the reversal of long term potentiation by low frequency stimulation at hippocampal CA1 synapses</article-title>. <source>J Biol Chem</source>
<year>2001</year>; <volume>276</volume>: <fpage>48108</fpage>&#x02013;48117.<pub-id pub-id-type="pmid">11679581</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal">Tavalin SJ, Colledge M, Hell JW, Langeberg LK, Huganir RL, Scott JD. <article-title>Regulation of GluR1 by the A-kinase anchoring protein 79 (AKAP79) signaling complex shares properties with long-term depression</article-title>. <source>J Neurosci</source>
<year>2002</year>; <volume>22</volume>: <fpage>3044</fpage>&#x02013;3051.<pub-id pub-id-type="pmid">11943807</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal">Lee H-K, Takamiya K, Han J-S, Man H, Kim C-H, Rumbaugh G et al. <article-title>Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory</article-title>. <source>Cell</source>
<year>2003</year>; <volume>112</volume>: <fpage>631</fpage>&#x02013;643.<pub-id pub-id-type="pmid">12628184</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal">Duman RS, Aghajanian GK, Sanacora G, Krystal JH. <article-title>Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants</article-title>. <source>Nat Med</source>
<year>2016</year>; <volume>22</volume>: <fpage>238</fpage>&#x02013;249.<pub-id pub-id-type="pmid">26937618</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal">Groc L, Choquet D, Chaouloff F. <article-title>The stress hormone corticosterone conditions AMPAR surface trafficking and synaptic potentiation</article-title>. <source>Nat Neurosci</source>
<year>2008</year>; <volume>11</volume>: <fpage>868</fpage>&#x02013;870.<pub-id pub-id-type="pmid">18622402</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal">Whitehead G, Jo J, Hogg EL, Piers T, Kim D-H, Seaton G et al. <article-title>Acute stress causes rapid synaptic insertion of Ca2&#x0002b; -permeable AMPA receptors to facilitate long-term potentiation in the hippocampus</article-title>. <source>Brain</source>
<year>2013</year>; <volume>136</volume>: <fpage>3753</fpage>&#x02013;3765.<pub-id pub-id-type="pmid">24271563</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal">Wiebe S, Blume WT, Girvin JP, Eliasziw M, Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. <article-title>A randomized, controlled trial of surgery for temporal-lobe epilepsy</article-title>. <source>N Engl J Med</source>
<year>2001</year>; <volume>345</volume>: <fpage>311</fpage>&#x02013;318.<pub-id pub-id-type="pmid">11484687</pub-id></mixed-citation></ref><ref id="bib42"><mixed-citation publication-type="journal">Araujo D, ACAC Santos, Velasco TR, Wichert-Ana L, Terra-Bustamante VC, Alexandre V et al. <article-title>Volumetric evidence of bilateral damage in unilateral mesial temporal lobe epilepsy</article-title>. <source>Epilepsia</source>
<year>2006</year>; <volume>47</volume>: <fpage>1354</fpage>&#x02013;1359.<pub-id pub-id-type="pmid">16922881</pub-id></mixed-citation></ref><ref id="bib43"><mixed-citation publication-type="journal">Guarnieri R, Walz R, Hallak JEC, Coimbra &#x000c9;, de Almeida E, Cescato MP et al. <article-title>Do psychiatric comorbidities predict postoperative seizure outcome in temporal lobe epilepsy surgery</article-title>? <source>Epilepsy Behav</source>
<year>2009</year>; <volume>14</volume>: <fpage>529</fpage>&#x02013;534.<pub-id pub-id-type="pmid">19186216</pub-id></mixed-citation></ref><ref id="bib44"><mixed-citation publication-type="journal">Nunes JC, Zakon DB, Claudino LS, Guarnieri R, Bastos A, Queiroz LP et al. <article-title>Hippocampal sclerosis and ipsilateral headache among mesial temporal lobe epilepsy patients</article-title>. <source>Seizure</source>
<year>2011</year>; <volume>20</volume>: <fpage>480</fpage>&#x02013;484.<pub-id pub-id-type="pmid">21439855</pub-id></mixed-citation></ref><ref id="bib45"><mixed-citation publication-type="journal">Pauli C, Thais ME, de O, Claudino LS, Bicalho MAH, Bastos AC, Guarnieri R et al. <article-title>Predictors of quality of life in patients with refractory mesial temporal lobe epilepsy</article-title>. <source>Epilepsy Behav</source>
<year>2012</year>; <volume>25</volume>: <fpage>208</fpage>&#x02013;213.<pub-id pub-id-type="pmid">23032134</pub-id></mixed-citation></ref><ref id="bib46"><mixed-citation publication-type="journal">Velasco TR, Wichert-Ana L, Mathern GW, Ara&#x000fa;jo D, Walz R, Bianchin MM et al. <article-title>Utility of ictal single photon emission computed tomography in mesial temporal lobe epilepsy with hippocampal atrophy: a randomized trial</article-title>. <source>Neurosurgery</source>
<year>2011</year>; <volume>68</volume>: <fpage>431</fpage>&#x02013;436.<pub-id pub-id-type="pmid">21135733</pub-id></mixed-citation></ref><ref id="bib47"><mixed-citation publication-type="journal">de Lemos Zingano B, Guarnieri R, Diaz AP, Schwarzbold ML, Bicalho MAH, Claudino LS et al. <article-title>Validation of diagnostic tests for depressive disorder in drug-resistant mesial temporal lobe epilepsy</article-title>. <source>Epilepsy Behav</source>
<year>2015</year>; <volume>50</volume>: <fpage>61</fpage>&#x02013;66.<pub-id pub-id-type="pmid">26119622</pub-id></mixed-citation></ref><ref id="bib48"><mixed-citation publication-type="journal">Hockey B, Leslie K, Williams D. <article-title>Dexamethasone for intracranial neurosurgery and anaesthesia</article-title>. <source>J Clin Neurosci</source>
<year>2009</year>; <volume>16</volume>: <fpage>1389</fpage>&#x02013;1393.<pub-id pub-id-type="pmid">19665383</pub-id></mixed-citation></ref><ref id="bib49"><mixed-citation publication-type="other">Chimmer BP, Funder JW In: Brunton L, Chabner B, Knollman B (eds). Goodman &#x00026; Gilman's The Pharmacological Basis of Therapeutics. 12th edn. Mc Graw Hill Medical: New York, NY, USA, 2011, pp 1209&#x02013;1235.</mixed-citation></ref><ref id="bib50"><mixed-citation publication-type="journal">Ronsoni MF, Remor AP, Lopes MW, Hohl A, Troncoso IHZ, Leal RB et al. <article-title>Mitochondrial respiration chain enzymatic activities in the human brain: methodological implications for tissue sampling and storage</article-title>. <source>Neurochem Res</source>
<year>2016</year>; <volume>41</volume>: <fpage>880</fpage>&#x02013;891.<pub-id pub-id-type="pmid">26586405</pub-id></mixed-citation></ref><ref id="bib51"><mixed-citation publication-type="journal">Costa AP, Lopes MW, Rieger DK, Barbosa SGR, Gon&#x000e7;alves FM, Xikota JC et al. <article-title>Differential activation of mitogen-activated protein kinases, ERK 1/2, p38MAPK and JNK p54/p46 during postnatal development of rat hippocampus</article-title>. <source>Neurochem Res</source>
<year>2016</year>; <volume>41</volume>: <fpage>1160</fpage>&#x02013;1169.<pub-id pub-id-type="pmid">26700434</pub-id></mixed-citation></ref><ref id="bib52"><mixed-citation publication-type="journal">Lopes MW, Lopes SC, Santos DB, Costa AP, Gon&#x000e7;alves FM, de Mello N et al. <article-title>Time course evaluation of behavioral impairments in the pilocarpine model of epilepsy</article-title>. <source>Epilepsy Behav</source>
<year>2016</year>; <volume>55</volume>: <fpage>92</fpage>&#x02013;100.<pub-id pub-id-type="pmid">26773677</pub-id></mixed-citation></ref><ref id="bib53"><mixed-citation publication-type="journal">Lopes MW, Soares FMS, De Mello N, Nunes JC, Cajado AG, De Brito D et al. <article-title>Time-dependent modulation of AMPA receptor phosphorylation and mRNA expression of NMDA receptors and glial glutamate transporters in the rat hippocampus and Cereb Cortex in a pilocarpine model of epilepsy</article-title>. <source>Exp Brain Res</source>
<year>2013</year>; <volume>226</volume>: <fpage>153</fpage>&#x02013;163.<pub-id pub-id-type="pmid">23392471</pub-id></mixed-citation></ref><ref id="bib54"><mixed-citation publication-type="journal">Lopes MW, Lopes SC, Costa AP, Gon&#x000e7;alves FM, Rieger DK, Peres TV et al. <article-title>Region-specific alterations of AMPA receptor phosphorylation and signaling pathways in the pilocarpine model of epilepsy</article-title>. <source>Neurochem Int</source>
<year>2015</year>; <volume>87</volume>: <fpage>22</fpage>&#x02013;33.<pub-id pub-id-type="pmid">25983036</pub-id></mixed-citation></ref><ref id="bib55"><mixed-citation publication-type="journal">Lopes MW, Soares FMS, de Mello N, Nunes JC, de Cordova FM, Walz R et al. <article-title>Time-dependent modulation of mitogen activated protein kinases and AKT in rat hippocampus and cortex in the pilocarpine model of epilepsy</article-title>. <source>Neurochem Res</source>
<year>2012</year>; <volume>37</volume>: <fpage>1868</fpage>&#x02013;1878.<pub-id pub-id-type="pmid">22614924</pub-id></mixed-citation></ref><ref id="bib56"><mixed-citation publication-type="journal">Ben J, Marques Gon&#x000e7;alves F, Alexandre Oliveira P, Vieira Peres T, Hohl A, Bainy Leal R et al. <article-title>Effects of pentylenetetrazole kindling on mitogen-activated protein kinases levels in neocortex and hippocampus of mice</article-title>. <source>Neurochem Res</source>
<year>2014</year>; <volume>39</volume>: <fpage>2492</fpage>&#x02013;2500.<pub-id pub-id-type="pmid">25316496</pub-id></mixed-citation></ref><ref id="bib57"><mixed-citation publication-type="journal">Peterson GL. <article-title>A simplification of the protein assay method of Lowry <italic>et al.</italic> which is more generally applicable</article-title>. <source>Anal Biochem</source>
<year>1977</year>; <volume>83</volume>: <fpage>346</fpage>&#x02013;356.<pub-id pub-id-type="pmid">603028</pub-id></mixed-citation></ref><ref id="bib58"><mixed-citation publication-type="other">Shonesy BC, Jalan-Sakrikar N, Cavener VS, Colbran RJ. <article-title>CaMKII: a molecular substrate for synaptic plasticity and memory</article-title>. <source>Prog Mol Biol Transl Sci</source>
<year>2014</year>; <fpage>61</fpage>&#x02013;87.<pub-id pub-id-type="pmid">24484698</pub-id></mixed-citation></ref><ref id="bib59"><mixed-citation publication-type="journal">Robison AJ. <article-title>Emerging role of CaMKII in neuropsychiatric disease</article-title>. <source>Trends Neurosci</source>
<year>2014</year>; <volume>37</volume>: <fpage>653</fpage>&#x02013;662.<pub-id pub-id-type="pmid">25087161</pub-id></mixed-citation></ref><ref id="bib60"><mixed-citation publication-type="journal">Sarabdjitsingh RA, Jo&#x000eb;ls M. <article-title>Rapid corticosteroid actions on synaptic plasticity in the mouse basolateral amygdala: relevance of recent stress history and &#x003b2;-adrenergic signaling</article-title>. <source>Neurobiol Learn Mem</source>
<year>2014</year>; <volume>112</volume>: <fpage>168</fpage>&#x02013;175.<pub-id pub-id-type="pmid">24513633</pub-id></mixed-citation></ref><ref id="bib61"><mixed-citation publication-type="journal">Sarabdjitsingh RA, Conway-Campbell BL, Leggett JD, Waite EJ, Meijer OC, de Kloet ER et al. <article-title>Stress responsiveness varies over the ultradian glucocorticoid cycle in a brain-region-specific manner</article-title>. <source>Endocrinology</source>
<year>2010</year>; <volume>151</volume>: <fpage>5369</fpage>&#x02013;5379.<pub-id pub-id-type="pmid">20861228</pub-id></mixed-citation></ref><ref id="bib62"><mixed-citation publication-type="journal">Henckens MJAG, van Wingen GA, Jo&#x000eb;ls M, Fern&#x000e1;ndez G. <article-title>Corticosteroid induced decoupling of the amygdala in men</article-title>. <source>Cereb Cortex</source>
<year>2012</year>; <volume>22</volume>: <fpage>2336</fpage>&#x02013;2345.<pub-id pub-id-type="pmid">22079927</pub-id></mixed-citation></ref><ref id="bib63"><mixed-citation publication-type="journal">Caudal D, Rame M, Jay TM, Godsil BP. <article-title>Dynamic regulation of AMPAR phosphorylation in vivo following acute behavioral stress</article-title>. <source>Cell Mol Neurobiol</source>
<year>2016</year>; <volume>36</volume>: <fpage>1331</fpage>&#x02013;1342.<pub-id pub-id-type="pmid">26814839</pub-id></mixed-citation></ref><ref id="bib64"><mixed-citation publication-type="journal">Karst H, Berger S, Erdmann G, Sch&#x000fc;tz G, Jo&#x000eb;ls M. <article-title>Metaplasticity of amygdalar responses to the stress hormone corticosterone</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2010</year>; <volume>107</volume>: <fpage>14449</fpage>&#x02013;14454.<pub-id pub-id-type="pmid">20663957</pub-id></mixed-citation></ref><ref id="bib65"><mixed-citation publication-type="journal">Lovallo WR, Robinson JL, Glahn DC, Fox PT. <article-title>Acute effects of hydrocortisone on the human brain: an fMRI study</article-title>. <source>Psychoneuroendocrinology</source>
<year>2010</year>; <volume>35</volume>: <fpage>15</fpage>&#x02013;20.<pub-id pub-id-type="pmid">19836143</pub-id></mixed-citation></ref><ref id="bib66"><mixed-citation publication-type="other">Markowitsch HJ,StaniloiuA. The contribution of the amygdala for the stablishing and mantaining an autonomous self autobiographical memory. Insights Into the Amygdala: Structure, Function and Implications for Disorders. Nova Science Publishers: 2012, pp 277&#x02013;318.</mixed-citation></ref><ref id="bib67"><mixed-citation publication-type="journal">Siebert M, Markowitsch HJ, Bartel P. <article-title>Amygdala, affect and cognition: Evidence from 10 patients with Urbach-Wiethe disease</article-title>. <source>Brain</source>
<year>2003</year>; <volume>126</volume>: <fpage>2627</fpage>&#x02013;2637.<pub-id pub-id-type="pmid">12937075</pub-id></mixed-citation></ref><ref id="bib68"><mixed-citation publication-type="journal">Yang TT, Menon V, Eliez S, Blasey C, White CD, Reid AJ et al. <article-title>Amygdalar activation associated with positive and negative facial expressions</article-title>. <source>Neuroreport</source>
<year>2002</year>; <volume>13</volume>: <fpage>1737</fpage>&#x02013;1741.<pub-id pub-id-type="pmid">12395114</pub-id></mixed-citation></ref><ref id="bib69"><mixed-citation publication-type="journal">Namburi P, Beyeler A, Yorozu S, Calhoon GG, Halbert SA, Wichmann R et al. <article-title>A circuit mechanism for differentiating positive and negative associations</article-title>. <source>Nature</source>
<year>2015</year>; <volume>520</volume>: <fpage>675</fpage>&#x02013;678.<pub-id pub-id-type="pmid">25925480</pub-id></mixed-citation></ref><ref id="bib70"><mixed-citation publication-type="journal">Cahill L, Babinsky R, Markowitsch HJ, McGaugh JL. <article-title>The amygdala and emotional memory</article-title>. <source>Nature</source>
<year>1995</year>; <volume>377</volume>: <fpage>295</fpage>&#x02013;296.<pub-id pub-id-type="pmid">7566084</pub-id></mixed-citation></ref><ref id="bib71"><mixed-citation publication-type="journal">Kerner B, Jasinska AJ, DeYoung J, Almonte M, Choi O-W, Freimer NB. <article-title>Polymorphisms in the GRIA1 gene region in psychotic bipolar disorder</article-title>. <source>Am J Med Genet B</source>
<year>2009</year>; <volume>150B</volume>: <fpage>24</fpage>&#x02013;32.</mixed-citation></ref><ref id="bib72"><mixed-citation publication-type="journal">Magri C, Gardella R, Barlati SD, Podavini D, Iatropoulos P, Bonomi S et al. <article-title>Glutamate AMPA receptor subunit 1 gene (GRIA1) and DSM-IV-TR schizophrenia: A pilot case-control association study in an Italian sample</article-title>. <source>Am J Med Genet B</source>
<year>2006</year>; <volume>141B</volume>: <fpage>287</fpage>&#x02013;293.</mixed-citation></ref><ref id="bib73"><mixed-citation publication-type="journal">Hosokawa T, Mitsushima D, Kaneko R, Hayashi Y. <article-title>Stoichiometry and phosphoisotypes of hippocampal AMPA-type glutamate receptor phosphorylation</article-title>. <source>Neuron</source>
<year>2015</year>; <volume>85</volume>: <fpage>60</fpage>&#x02013;67.<pub-id pub-id-type="pmid">25533481</pub-id></mixed-citation></ref><ref id="bib74"><mixed-citation publication-type="journal">Diering GH, Heo S, Hussain NK, Liu B, Huganir RL. <article-title>Extensive phosphorylation of AMPA receptors in neurons</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2016</year>; <volume>113</volume>: <fpage>E4920</fpage>&#x02013;E4927.<pub-id pub-id-type="pmid">27482106</pub-id></mixed-citation></ref><ref id="bib75"><mixed-citation publication-type="journal">Yilmazer-Hanke DM, Wolf HK, Schramm J, Elger CE, Wiestler OD, Bl&#x000fc;mcke I. <article-title>Subregional pathology of the amygdala complex and entorhinal region in surgical specimens from patients with pharmacoresistant temporal lobe epilepsy</article-title>. <source>J Neuropathol Exp Neurol</source>
<year>2000</year>; <volume>59</volume>: <fpage>907</fpage>&#x02013;920.<pub-id pub-id-type="pmid">11079781</pub-id></mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Information</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tp2016251x1.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></back><floats-group><table-wrap id="tbl1"><label>Table 1</label><caption><title>Clinical, demographic, neuroradiological, neurophysiological and surgical variables of patients with mesial temporal lobe epilepsy related to hippocampal sclerosis according to dexamethasone treatment</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>Variables</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>All cases</italic>, n=<italic>31</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>No dexamethasone</italic>, n=<italic>11</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>Dexamethasone</italic>, n=<italic>20</italic></th><th align="center" valign="top" charoff="50">P<italic>-value</italic></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Gender</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="char" valign="top" char="(" charoff="50">18 (58.1)</td><td align="char" valign="top" char="(" charoff="50">4 (36.4)</td><td align="char" valign="top" char="(" charoff="50">14 (70.0)</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="char" valign="top" char="(" charoff="50">13 (41.9)</td><td align="char" valign="top" char="(" charoff="50">7 (63.6)</td><td align="char" valign="top" char="(" charoff="50">6 (30.0)</td><td align="char" valign="top" char="." charoff="50"><bold>0.13</bold></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Race</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Caucasian</td><td align="char" valign="top" char="(" charoff="50">27 (87.1)</td><td align="char" valign="top" char="(" charoff="50">9 (81.8)</td><td align="char" valign="top" char="(" charoff="50">18 (90.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Others</td><td align="char" valign="top" char="(" charoff="50">04 (12.9)</td><td align="char" valign="top" char="(" charoff="50">2 (16.2)</td><td align="char" valign="top" char="(" charoff="50">2 (10.0)</td><td align="char" valign="top" char="." charoff="50">0.60</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Marital status</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Single</td><td align="char" valign="top" char="(" charoff="50">17 (54.8)</td><td align="char" valign="top" char="(" charoff="50">8 (72.7)</td><td align="char" valign="top" char="(" charoff="50">9 (45.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Married</td><td align="char" valign="top" char="(" charoff="50">10 (32.3)</td><td align="char" valign="top" char="(" charoff="50">2 (18.2)</td><td align="char" valign="top" char="(" charoff="50">8 (40.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Divorced or widower</td><td align="char" valign="top" char="(" charoff="50">4 (12.9)</td><td align="char" valign="top" char="(" charoff="50">1 (9.1)</td><td align="char" valign="top" char="(" charoff="50">3 (15.0)</td><td align="char" valign="top" char="." charoff="50">0.33</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Current work activity</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Working</td><td align="char" valign="top" char="(" charoff="50">11 (35.5)</td><td align="char" valign="top" char="(" charoff="50">4 (36.4)</td><td align="char" valign="top" char="(" charoff="50">7 (35.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Health insurance</td><td align="char" valign="top" char="(" charoff="50">4 (12.9)</td><td align="char" valign="top" char="(" charoff="50">7 (63.6)</td><td align="char" valign="top" char="(" charoff="50">9 (45.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Not working</td><td align="char" valign="top" char="(" charoff="50">16 (51.6)</td><td align="char" valign="top" char="(" charoff="50">0 (0.0)</td><td align="char" valign="top" char="(" charoff="50">4 (20.0)</td><td align="char" valign="top" char="." charoff="50">0.26</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>History of initial precipitant injury</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">7 (22.6)</td><td align="char" valign="top" char="(" charoff="50">3 (27.3)</td><td align="char" valign="top" char="(" charoff="50">4 (20.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">24 (77.4)</td><td align="char" valign="top" char="(" charoff="50">8 (72.7)</td><td align="char" valign="top" char="(" charoff="50">16 (80.0)</td><td align="char" valign="top" char="." charoff="50">0.68</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Family history of epilepsy</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">12 (38.7)</td><td align="char" valign="top" char="(" charoff="50">4 (36.4)</td><td align="char" valign="top" char="(" charoff="50">8 (40.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Second-degree or distant</td><td align="char" valign="top" char="(" charoff="50">10 (32.3)</td><td align="char" valign="top" char="(" charoff="50">2 (18.2)</td><td align="char" valign="top" char="(" charoff="50">8 (40.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;First- degree</td><td align="char" valign="top" char="(" charoff="50">6 (19.4)</td><td align="char" valign="top" char="(" charoff="50">3 (27.3)</td><td align="char" valign="top" char="(" charoff="50">3 (15.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Unknown</td><td align="char" valign="top" char="(" charoff="50">3 (9.7)</td><td align="char" valign="top" char="(" charoff="50">2 (18.2)</td><td align="char" valign="top" char="(" charoff="50">1 (5.9)</td><td align="char" valign="top" char="." charoff="50">0.41</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>MRI hippocampal sclerosis</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Right side</td><td align="char" valign="top" char="(" charoff="50">16 (51.6)</td><td align="char" valign="top" char="(" charoff="50">4 (36.4)</td><td align="char" valign="top" char="(" charoff="50">12 (60.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Left side</td><td align="char" valign="top" char="(" charoff="50">15 (48.4)</td><td align="char" valign="top" char="(" charoff="50">7 (63.6)</td><td align="char" valign="top" char="(" charoff="50">8 (40.0)</td><td align="char" valign="top" char="." charoff="50">0.27</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Antiepileptic drugs regimen</italic><xref ref-type="fn" rid="t1-fn2">a</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Monotherapy</td><td align="char" valign="top" char="(" charoff="50">9 (29.0)</td><td align="char" valign="top" char="(" charoff="50">6 (54.5)</td><td align="char" valign="top" char="(" charoff="50">3 (15.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Two or more drugs</td><td align="char" valign="top" char="(" charoff="50">23 (71.0)</td><td align="char" valign="top" char="(" charoff="50">5 (45.5)</td><td align="char" valign="top" char="(" charoff="50">17 (85.0)</td><td align="char" valign="top" char="." charoff="50"><bold>0.04</bold></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Benzodiazepines</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">15 (48.4)</td><td align="char" valign="top" char="(" charoff="50">7 (63.6)</td><td align="char" valign="top" char="(" charoff="50">9 (45.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">16 (51.6)</td><td align="char" valign="top" char="(" charoff="50">4 (36.4)</td><td align="char" valign="top" char="(" charoff="50">11 (55.0)</td><td align="char" valign="top" char="." charoff="50">0.46</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Antiepileptic drugs</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Carbamazepine</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">6 (19.4)</td><td align="char" valign="top" char="(" charoff="50">4 (36.4)</td><td align="char" valign="top" char="(" charoff="50">2 (10.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">29 (80.6)</td><td align="char" valign="top" char="(" charoff="50">7 (63.3)</td><td align="char" valign="top" char="(" charoff="50">18 (90.0)</td><td align="char" valign="top" char="." charoff="50">0.16</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>&#x02003;</italic>Phenobarbital</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">19 (61.3)</td><td align="char" valign="top" char="(" charoff="50">9 (81.2)</td><td align="char" valign="top" char="(" charoff="50">10 (50.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">12 (38.7)</td><td align="char" valign="top" char="(" charoff="50">2 (18.2)</td><td align="char" valign="top" char="(" charoff="50">10 (50.0)</td><td align="char" valign="top" char="." charoff="50"><bold>0.13</bold></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">&#x02003;Diphenilhydantoin</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">28 (90.3)</td><td align="char" valign="top" char="(" charoff="50">11 (100.0)</td><td align="char" valign="top" char="(" charoff="50">17 (85.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">3 (9.7)</td><td align="char" valign="top" char="(" charoff="50">0 (0.0)</td><td align="char" valign="top" char="(" charoff="50">03 (15.0)</td><td align="char" valign="top" char="." charoff="50">0.54</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">&#x02003;Valproic acid</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">29 (93.5)</td><td align="char" valign="top" char="(" charoff="50">9 (81.8)</td><td align="char" valign="top" char="(" charoff="50">18 (90.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">4 (12.9)</td><td align="char" valign="top" char="(" charoff="50">2 (18.2)</td><td align="char" valign="top" char="(" charoff="50">2 (10.0)</td><td align="char" valign="top" char="." charoff="50">0.60</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">&#x02003;Lamotrigin</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">27 (87.1)</td><td align="char" valign="top" char="(" charoff="50">9 (81.8)</td><td align="char" valign="top" char="(" charoff="50">18 (90.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">4 (12.9)</td><td align="char" valign="top" char="(" charoff="50">2 (18.2)</td><td align="char" valign="top" char="(" charoff="50">2 (10.0)</td><td align="char" valign="top" char="." charoff="50">0.60</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">&#x02003;Topiramate</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;No</td><td align="char" valign="top" char="(" charoff="50">29 (93.5)</td><td align="char" valign="top" char="(" charoff="50">11 (100.0)</td><td align="char" valign="top" char="(" charoff="50">18 (90.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Yes</td><td align="char" valign="top" char="(" charoff="50">2 (6.5)</td><td align="char" valign="top" char="(" charoff="50">0 (0.0)</td><td align="char" valign="top" char="(" charoff="50">2 (10.0)</td><td align="char" valign="top" char="." charoff="50">0.53</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Hand dominance</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Right</td><td align="char" valign="top" char="(" charoff="50">27 (87.1)</td><td align="char" valign="top" char="(" charoff="50">9 (81.8)</td><td align="char" valign="top" char="(" charoff="50">18 (90.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Non-right</td><td align="char" valign="top" char="(" charoff="50">4 (12.9)</td><td align="char" valign="top" char="(" charoff="50">2 (18.2)</td><td align="char" valign="top" char="(" charoff="50">2 (10.0)</td><td align="char" valign="top" char="." charoff="50">0.60</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Psychiatric comorbidities</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;No diagnosis</td><td align="char" valign="top" char="(" charoff="50">14 (45.2)</td><td align="char" valign="top" char="(" charoff="50">4 (36.3)</td><td align="char" valign="top" char="(" charoff="50">10 (50.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Depressive disorder</td><td align="char" valign="top" char="(" charoff="50">8 (25.8)</td><td align="char" valign="top" char="(" charoff="50">2 (18.2)</td><td align="char" valign="top" char="(" charoff="50">6 (30.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Anxiety disorder<xref ref-type="fn" rid="t1-fn3">b</xref></td><td align="char" valign="top" char="(" charoff="50">3 (9.7)</td><td align="char" valign="top" char="(" charoff="50">2 (18.2)</td><td align="char" valign="top" char="(" charoff="50">1 (5.0)</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Other psychiatric conditions<xref ref-type="fn" rid="t1-fn4">c</xref></td><td align="char" valign="top" char="(" charoff="50">6 (19.4)</td><td align="char" valign="top" char="(" charoff="50">3 (27.3)</td><td align="char" valign="top" char="(" charoff="50">3 (15.0)</td><td align="char" valign="top" char="." charoff="50">0.48</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Mean (s.e.)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Age (years)</td><td align="char" valign="top" char="(" charoff="50">36.4 (2.2)</td><td align="char" valign="top" char="(" charoff="50">34.6 (3.8)</td><td align="char" valign="top" char="(" charoff="50">37.3 (2.7)</td><td align="char" valign="top" char="." charoff="50">0.57</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Education (years)</td><td align="char" valign="top" char="(" charoff="50">6.6 (0.5)</td><td align="char" valign="top" char="(" charoff="50">6 (1.0)</td><td align="char" valign="top" char="(" charoff="50">6.9 (0.6)</td><td align="char" valign="top" char="." charoff="50">0.43</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Disease duration (years)</td><td align="char" valign="top" char="(" charoff="50">24.3 (2.0)</td><td align="char" valign="top" char="(" charoff="50">25.8 (3.1)</td><td align="char" valign="top" char="(" charoff="50">23.5 (2.6)</td><td align="char" valign="top" char="." charoff="50">0.60</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Monthly seizure frequency</td><td align="char" valign="top" char="(" charoff="50">7.5 (0.9)</td><td align="char" valign="top" char="(" charoff="50">4.9 (0.9)</td><td align="char" valign="top" char="(" charoff="50">8.5 (1.1)</td><td align="char" valign="top" char="." charoff="50"><bold>0.04</bold></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;QOLIE-31</td><td align="char" valign="top" char="(" charoff="50">35.2 (2.7)</td><td align="char" valign="top" char="(" charoff="50">38.2 (3.8)</td><td align="char" valign="top" char="(" charoff="50">33.5 (3.7)</td><td align="char" valign="top" char="." charoff="50">0.43</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Intraoperative parameters</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Mean arterial pressure</td><td align="char" valign="top" char="(" charoff="50">67.5 (1.7)</td><td align="char" valign="top" char="(" charoff="50">64 (3.0)</td><td align="char" valign="top" char="(" charoff="50">68.8 (2.1)</td><td align="char" valign="top" char="." charoff="50">0.30</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Heart rate</td><td align="char" valign="top" char="(" charoff="50">73.7 (2.2)</td><td align="char" valign="top" char="(" charoff="50">70 (4.1)</td><td align="char" valign="top" char="(" charoff="50">75 (2.7)</td><td align="char" valign="top" char="." charoff="50">0.30</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Respiratory frequency</td><td align="char" valign="top" char="(" charoff="50">11.6 (0.3)</td><td align="char" valign="top" char="(" charoff="50">11.7 (0.5)</td><td align="char" valign="top" char="(" charoff="50">11.5 (0.4)</td><td align="char" valign="top" char="." charoff="50">0.88</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Biochemical analysis of the blood</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;pH</td><td align="char" valign="top" char="(" charoff="50">7.41 (0.07)</td><td align="char" valign="top" char="(" charoff="50">7.41 (0.01)</td><td align="char" valign="top" char="(" charoff="50">7.42 (0.01)</td><td align="char" valign="top" char="." charoff="50">0.66</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;PCO<sub>2</sub></td><td align="char" valign="top" char="(" charoff="50">28 (0.8)</td><td align="char" valign="top" char="(" charoff="50">29.6 (1.5)</td><td align="char" valign="top" char="(" charoff="50">28.1 (0.9)</td><td align="char" valign="top" char="." charoff="50">0.35</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;HCO<sub>3</sub></td><td align="char" valign="top" char="(" charoff="50">20.0 (0.3)</td><td align="char" valign="top" char="(" charoff="50">20.7 (0.6)</td><td align="char" valign="top" char="(" charoff="50">19.6 (0.3)</td><td align="char" valign="top" char="." charoff="50">0.20</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;PO<sub>2</sub></td><td align="char" valign="top" char="(" charoff="50">229 (11.0)</td><td align="char" valign="top" char="(" charoff="50">214.6 (25.1)</td><td align="char" valign="top" char="(" charoff="50">237.8 (10.3)</td><td align="char" valign="top" char="." charoff="50">0.32</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;O<sub>2</sub> saturation</td><td align="char" valign="top" char="(" charoff="50">99.7 (0.04)</td><td align="char" valign="top" char="(" charoff="50">99.6 (0.08)</td><td align="char" valign="top" char="(" charoff="50">99.7 (0.05)</td><td align="char" valign="top" char="." charoff="50">0.90</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Hematocrit</td><td align="char" valign="top" char="(" charoff="50">35.0 (0.7)</td><td align="char" valign="top" char="(" charoff="50">33.9 (1.4)</td><td align="char" valign="top" char="(" charoff="50">35.6 (0.8)</td><td align="char" valign="top" char="." charoff="50">0.27</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Hemoglobin</td><td align="char" valign="top" char="(" charoff="50">12.5 (0.9)</td><td align="char" valign="top" char="(" charoff="50">14.9 (2.9)</td><td align="char" valign="top" char="(" charoff="50">11.7 (0.3)</td><td align="char" valign="top" char="." charoff="50">0.26</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Glucose</td><td align="char" valign="top" char="(" charoff="50">116.3 (4.9)</td><td align="char" valign="top" char="(" charoff="50">103.4 (6.4)</td><td align="char" valign="top" char="(" charoff="50">121 (6.0)</td><td align="char" valign="top" char="." charoff="50"><bold>0.10</bold></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Sodium</td><td align="char" valign="top" char="(" charoff="50">138.2 (3.9)</td><td align="char" valign="top" char="(" charoff="50">136.9 (1.2)</td><td align="char" valign="top" char="(" charoff="50">139 (1.7)</td><td align="char" valign="top" char="." charoff="50">0.20</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Potassium</td><td align="char" valign="top" char="(" charoff="50">4.1 (0.1)</td><td align="char" valign="top" char="(" charoff="50">4.2 (0.2)</td><td align="char" valign="top" char="(" charoff="50">4.1 (0.1)</td><td align="char" valign="top" char="." charoff="50">0.63</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Ionic calcium</td><td align="char" valign="top" char="(" charoff="50">4.2 (0.1)</td><td align="char" valign="top" char="(" charoff="50">4.1 (0.1)</td><td align="char" valign="top" char="(" charoff="50">4.2 (0.2)</td><td align="char" valign="top" char="." charoff="50">0.95</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Magnesium</td><td align="char" valign="top" char="(" charoff="50">0.4 (0.08)</td><td align="char" valign="top" char="(" charoff="50">0.4 (0.02)</td><td align="char" valign="top" char="(" charoff="50">0.5 (0.01)</td><td align="char" valign="top" char="." charoff="50">0.15</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lactic acid</td><td align="char" valign="top" char="(" charoff="50">2.1 (0.2)</td><td align="char" valign="top" char="(" charoff="50">1.7 (0.3)</td><td align="char" valign="top" char="(" charoff="50">2.3 (0.3)</td><td align="char" valign="top" char="." charoff="50">0.22</td></tr><tr><td align="left" valign="top" charoff="50">Storage time of samples (months)<xref ref-type="fn" rid="t1-fn2">a</xref></td><td align="char" valign="top" char="(" charoff="50">24 (1.5)</td><td align="char" valign="top" char="(" charoff="50">28.2 (2.9)</td><td align="char" valign="top" char="(" charoff="50">21.5 (1.7)</td><td align="char" valign="top" char="." charoff="50"><bold>0.05</bold></td></tr><tr><td align="left" valign="top" charoff="50">Time since last seizure (hours)<xref ref-type="fn" rid="t1-fn5">d</xref></td><td align="char" valign="top" char="(" charoff="50">225 (82)</td><td align="char" valign="top" char="(" charoff="50">200 (63)</td><td align="char" valign="top" char="(" charoff="50">239 (122)</td><td align="char" valign="top" char="." charoff="50">0.82</td></tr><tr><td align="left" valign="top" charoff="50">Time for CX sampling (min)<xref ref-type="fn" rid="t1-fn6">e</xref></td><td align="char" valign="top" char="(" charoff="50">188.3 (7.1)</td><td align="char" valign="top" char="(" charoff="50">184.8 (10.3)</td><td align="char" valign="top" char="(" charoff="50">190 (9.7)</td><td align="char" valign="top" char="." charoff="50">0.71</td></tr><tr><td align="left" valign="top" charoff="50">Time for AMY/HIP sampling (min)<xref ref-type="fn" rid="t1-fn7">f</xref></td><td align="char" valign="top" char="(" charoff="50">260.1 (10.0)</td><td align="char" valign="top" char="(" charoff="50">254.6 (16.9)</td><td align="char" valign="top" char="(" charoff="50">262.8 (12.8)</td><td align="char" valign="top" char="." charoff="50">0.78</td></tr><tr><td align="left" valign="top" charoff="50">Time of HIP manipulation (min)<xref ref-type="fn" rid="t1-fn8">g</xref></td><td align="char" valign="top" char="(" charoff="50">11.2 (0.9)</td><td align="char" valign="top" char="(" charoff="50">11.7 (1.3)</td><td align="char" valign="top" char="(" charoff="50">11.1 (1.2)</td><td align="char" valign="top" char="." charoff="50">0.70</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: AMY, amygdala; CX, middle temporal neocortex gyrus; HIP, hippocampus; MRI, magnetic resonance imaging; QOLIE-31, Quality of Life in Epilepsy Inventory-31.</p></fn><fn id="t1-fn2"><label>a</label><p>Time course since brain tissue sampling and the homogenization for neurochemical evaluation (range 8 to 39 months).</p></fn><fn id="t1-fn3"><label>b</label><p>Anxiety disorders: generalized anxiety disorder (two patients in the non-dexamethasone group), social phobia (one patient in non-DEX group).</p></fn><fn id="t1-fn4"><label>c</label><p>Other psychiatric conditions: three patients with dysphoric disorder of epilepsy (one in the non-DEXA group), two patients with postictal psychosis (in the non-DEXA group), one patient with postictal anxiety (in the DEXA group).</p></fn><fn id="t1-fn5"><label>d</label><p>Time course since the last seizure attack occurrence and brain tissue sampling (range 12 to 590&#x02009;h).</p></fn><fn id="t1-fn6"><label>e</label><p>Time course since anesthesia induction until CX tissue sampling (range 119 to 255&#x02009;min).</p></fn><fn id="t1-fn7"><label>f</label><p>Time course since anesthesia induction until AMY/HIP tissue sampling (range 160 to 360&#x02009;min).</p></fn><fn id="t1-fn8"><label>g</label><p>Time course since HIP vessels thermo-coagulation started until the complete resection of the HIP (range 5 to 25&#x02009;min). Variables showing a '<italic>P</italic>' level of significance &#x0003c;0.15 are in bold.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Comparison of phospho-GluA1-Ser831 and phospho-GluA1-Ser845 levels variation in the middle temporal neocortex, amygdala and head of the hippocampus according to dexamethasone treatment</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>Variables</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>All cases</italic>, n=<italic>31, mean (s.e.)</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>No dexamethasone</italic>, n=<italic>11, mean (s.e.)</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>Dexamethasone</italic>, n=<italic>20, Mean (s.e.)</italic></th><th align="center" valign="top" char="." charoff="50">P<italic>-value</italic></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Middle temporal neocortex</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-GluA1-Ser831</td><td align="char" valign="top" char="(" charoff="50">118.6 (3.2)</td><td align="char" valign="top" char="(" charoff="50">126.9 (6.3)</td><td align="char" valign="top" char="(" charoff="50">114.3 (3.2)</td><td align="char" valign="top" char="." charoff="50">0.06<xref ref-type="fn" rid="t2-fn1">a</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-GluA1-Ser845</td><td align="char" valign="top" char="(" charoff="50">112.4 (3.0)</td><td align="char" valign="top" char="(" charoff="50">103.1 (4.1)</td><td align="char" valign="top" char="(" charoff="50">117.3 (3.6)</td><td align="char" valign="top" char="." charoff="50">0.02<xref ref-type="fn" rid="t2-fn2">b</xref></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Amygdala</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-GluA1-Ser831</td><td align="char" valign="top" char="(" charoff="50">109.3 (3.0)</td><td align="char" valign="top" char="(" charoff="50">122.8 (4.6)</td><td align="char" valign="top" char="(" charoff="50">101.9 (2.8)</td><td align="char" valign="top" char="." charoff="50">0.0003<xref ref-type="fn" rid="t2-fn3">c</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-GluA1-Ser845</td><td align="char" valign="top" char="(" charoff="50">108.1 (3.3)</td><td align="char" valign="top" char="(" charoff="50">108.2 (6.0)</td><td align="char" valign="top" char="(" charoff="50">108.0 (4.1)</td><td align="char" valign="top" char="." charoff="50">0.98</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Hippocampus</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-GluA1-Ser831</td><td align="char" valign="top" char="(" charoff="50">97.0 (3.7)</td><td align="char" valign="top" char="(" charoff="50">105.2 (7.2)</td><td align="char" valign="top" char="(" charoff="50">92.5 (4.0)</td><td align="char" valign="top" char="." charoff="50">0.10<xref ref-type="fn" rid="t2-fn4">d</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-GluA1-Ser845</td><td align="char" valign="top" char="(" charoff="50">104.2 (3.6)</td><td align="char" valign="top" char="(" charoff="50">100.5 (7.8)</td><td align="char" valign="top" char="(" charoff="50">106.3 (3.7)</td><td align="char" valign="top" char="." charoff="50">0.46</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><label>a</label><p>Non-significant trend of 12.6&#x00025; decrease in the neocortex levels of P-GluA1-Ser831;</p></fn><fn id="t2-fn2"><label>b</label><p>Non-significant trend of 14.2&#x00025; decrease in the neocortex levels of P-GluA1-Ser845;</p></fn><fn id="t2-fn3"><label>c</label><p>Significant decrease of 20.9&#x00025; in the amygdala levels of P-GluA1-Ser831;</p></fn><fn id="t2-fn4"><label>d</label><p>Non-significant trend of 12.7&#x00025; decrease in the hippocampus levels of P-GluA1-Ser831.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Variables associated with amygdala levels of phospho-GluA1-Ser831</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center" char="."/><col align="center" char="."/><col align="center" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>Variables</italic></th><th colspan="3" align="center" valign="top" charoff="50"><italic>Amygdala levels of phospho-GluA1-Ser831</italic></th><th align="center" valign="top" char="." charoff="50">P-<italic>value</italic></th></tr><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th colspan="3" align="center" valign="top" charoff="50"><italic>Univariate analysis</italic><xref ref-type="fn" rid="t3-fn2">a</xref></th><th align="center" valign="top" char="." charoff="50">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50"><italic>Gender</italic></td><td colspan="3" align="center" valign="top" charoff="50"><italic>Mean (s.e.)</italic></td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td colspan="3" align="center" valign="top" charoff="50">103 (3.6)</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td colspan="3" align="center" valign="top" charoff="50">117.4 (4.5)</td><td align="char" valign="top" char="." charoff="50">0.02<xref ref-type="fn" rid="t3-fn2">a</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>AEDs regimen</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Monotherapy</td><td colspan="3" align="center" valign="top" charoff="50">114 (5.0)</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Two AEDs or more</td><td colspan="3" align="center" valign="top" charoff="50">109 (3.9)</td><td align="char" valign="top" char="." charoff="50">0.51<xref ref-type="fn" rid="t3-fn2">a</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Phenobarbital treatment</italic></td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;No</td><td colspan="3" align="center" valign="top" charoff="50">111.7 (3.8)</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Yes</td><td colspan="3" align="center" valign="top" charoff="50">105.4 (4.9)</td><td align="char" valign="top" char="." charoff="50">0.32<xref ref-type="fn" rid="t3-fn2">a</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">B</td><td align="center" valign="top" char="." charoff="50">r</td><td align="center" valign="top" char="." charoff="50">r<sup>2</sup></td><td align="center" valign="top" char="." charoff="50">P-value</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Univariate linear regressions</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Monthly seizure frequency</td><td align="center" valign="top" charoff="50">&#x02212;0.71</td><td align="center" valign="top" char="." charoff="50">0.21</td><td align="center" valign="top" char="." charoff="50">0.05</td><td align="char" valign="top" char="." charoff="50">0.26<xref ref-type="fn" rid="t3-fn3">b</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Serum glucose</td><td align="center" valign="top" charoff="50">&#x02212;0.19</td><td align="center" valign="top" char="." charoff="50">0.32</td><td align="center" valign="top" char="." charoff="50">0.10</td><td align="char" valign="top" char="." charoff="50">0.12<xref ref-type="fn" rid="t3-fn3">b</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Storage time of samples (months)</td><td align="center" valign="top" charoff="50">0.36</td><td align="center" valign="top" char="." charoff="50">0.19</td><td align="center" valign="top" char="." charoff="50">0.04</td><td align="char" valign="top" char="." charoff="50">0.30<xref ref-type="fn" rid="t3-fn3">b</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Dexamethasone dose (mg&#x02009;kg<sup>&#x02212;1</sup>)</td><td align="center" valign="top" charoff="50">&#x02212;145.6</td><td align="char" valign="top" char="." charoff="50">0.69</td><td align="center" valign="top" char="." charoff="50">0.48</td><td align="char" valign="top" char="." charoff="50">0.00002<xref ref-type="fn" rid="t3-fn3">b</xref></td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Multiple linear regression</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Constant</td><td align="center" valign="top" charoff="50">134.8</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.00001</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="center" valign="top" charoff="50">&#x02212;0.90</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.85</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Serum glucose</td><td align="center" valign="top" charoff="50">&#x02212;0.10</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.33</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Dexamethasone dose (mg&#x02009;kg<sup>&#x02212;1</sup>)</td><td align="char" valign="top" char="." charoff="50">&#x02212;131.1</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="center" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.0003</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">0.73</td><td align="char" valign="top" char="." charoff="50">0.53</td><td align="char" valign="top" char="." charoff="50">0.001<xref ref-type="fn" rid="t3-fn4">c</xref></td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviation: AEDs, antiepileptic drugs.</p></fn><fn id="t3-fn2"><label>a</label><p>Univariate analysis by Student's <italic>t-</italic>test;</p></fn><fn id="t3-fn3"><label>b</label><p>Univariate analysis by linear regression;</p></fn><fn id="t3-fn4"><label>c</label><p>Level of significance for the multiple linear regression model.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4"><label>Table 4</label><caption><title>Effects of dexamethasone treatment on signal transduction molecules, glutamate receptors and transporters, and astrocyte markers in the amygdala according to dexamethasone treatment</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>Signal transduction molecules, astrocyte markers, and glutamate receptors and transporters</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>No dexamethasone,</italic> n=<italic>11, mean (s.e.)</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>Dexamethasone,</italic> n=<italic>20, mean (s.e.)</italic></th><th align="center" valign="top" char="." charoff="50">P<italic>-value</italic><xref ref-type="fn" rid="t4-fn2">a</xref></th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Enzymes acting directly upon GluA1-Ser831 site</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;PP1ca</td><td align="char" valign="top" char="(" charoff="50">94.6 (2.8)</td><td align="char" valign="top" char="(" charoff="50">94.8 (2.0)</td><td align="char" valign="top" char="." charoff="50">0.82</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;PKC activity</td><td align="char" valign="top" char="(" charoff="50">122.6 (5.5)</td><td align="char" valign="top" char="(" charoff="50">119.9 (5.4)</td><td align="char" valign="top" char="." charoff="50">0.76</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-CaMKII</td><td align="char" valign="top" char="(" charoff="50">127.6 (9.9)</td><td align="char" valign="top" char="(" charoff="50">105.2 (3.7)</td><td align="char" valign="top" char="." charoff="50"><bold>0.02</bold><xref ref-type="fn" rid="t4-fn3">b</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Total CaMKII</td><td align="char" valign="top" char="(" charoff="50">93.4 (2.4)</td><td align="char" valign="top" char="(" charoff="50">100.2 (2.4)</td><td align="char" valign="top" char="." charoff="50">0.08<xref ref-type="fn" rid="t4-fn2">a</xref></td></tr><tr><td colspan="4" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>Enzymes not acting upon GluA1-Ser831 site</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;PKA activity</td><td align="char" valign="top" char="(" charoff="50">120.9 (5.8)</td><td align="char" valign="top" char="(" charoff="50">125.1 (6.5)</td><td align="char" valign="top" char="." charoff="50">0.67</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-ERK1</td><td align="char" valign="top" char="(" charoff="50">98.6 (5.1)</td><td align="char" valign="top" char="(" charoff="50">91.6 (3.9)</td><td align="char" valign="top" char="." charoff="50">0.29</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-ERK2</td><td align="char" valign="top" char="(" charoff="50">96.6 (2.4)</td><td align="char" valign="top" char="(" charoff="50">98.8 (3.4)</td><td align="char" valign="top" char="." charoff="50">0.87</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-JNK1</td><td align="char" valign="top" char="(" charoff="50">99.8 (3.6)</td><td align="char" valign="top" char="(" charoff="50">100.4 (4.2)</td><td align="char" valign="top" char="." charoff="50">0.93</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-JNK2</td><td align="char" valign="top" char="(" charoff="50">100.68 (4.4)</td><td align="char" valign="top" char="(" charoff="50">99.5 (95.5)</td><td align="char" valign="top" char="." charoff="50">0.89</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-AKT</td><td align="char" valign="top" char="(" charoff="50">95.6 (2.4)</td><td align="char" valign="top" char="(" charoff="50">95.5 (2.0)</td><td align="char" valign="top" char="." charoff="50">0.75</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;P-p38</td><td align="char" valign="top" char="(" charoff="50">102.8 (2.8)</td><td align="char" valign="top" char="(" charoff="50">105.3 (2.3)</td><td align="char" valign="top" char="." charoff="50">0.52</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><italic>GLU receptors sub unities and transporters, and astrocyte markers</italic><xref ref-type="fn" rid="t4-fn4">c</xref></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;GluA1</td><td align="char" valign="top" char="(" charoff="50">96.8 (3.8)</td><td align="char" valign="top" char="(" charoff="50">97.8 (2.8)</td><td align="char" valign="top" char="." charoff="50">0.83</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;GFAP</td><td align="char" valign="top" char="(" charoff="50">110.7 (4.0)</td><td align="char" valign="top" char="(" charoff="50">106.8 (1.9)</td><td align="char" valign="top" char="." charoff="50">0.35</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;EAAT1</td><td align="char" valign="top" char="(" charoff="50">90.2 (4.3)</td><td align="char" valign="top" char="(" charoff="50">95.5 (3.5)</td><td align="char" valign="top" char="." charoff="50">0.36</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;EAAT2</td><td align="char" valign="top" char="(" charoff="50">98.1 (6.4)</td><td align="char" valign="top" char="(" charoff="50">94.1 (5.4)</td><td align="char" valign="top" char="." charoff="50">0.65</td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><p>Abbreviations: AMY, amygdala; DEXA, dexamethasone</p></fn><fn id="t4-fn2"><label>a</label><p>There was a trend (<italic>P</italic>=0.08) for a presence of higher levels of total CaMKII in the AMY of DEXA in comparison to non-DEXA patients;</p></fn><fn id="t4-fn3"><label>b</label><p>Concerning the enzymes affecting the P-GluA1-Ser831 levels, DEXA treatment decrease 22.4&#x00025; of P-CaMKII levels in the AMY, without affecting the PKC activity, P-CaMKII or PP1ca levels;</p></fn><fn id="t4-fn4"><label>c</label><p>GluA1=Levels of GluA1 subunit of glutamate AMPA receptor; GFAP=Levels of Glial Fibrilary Acidic Protein; EAAT1 and EAAT2=Levels of glial excitatory amino acid transporter (EAAT) type 1 and 2.</p></fn></table-wrap-foot></table-wrap></floats-group></article>